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We are not actually made for time. 
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Therefore we were not made for time.
We were made for eternity.
We are timeless creatures.
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chArActeristics
Down’s syndrome (DS) is a common genetic disorder affecting around 1 in 800 live births in the 
human population. The syndrome was first described by Down in 1866, in which he marked a col-
lection of symptoms observed in 10% of the children with intellectual disability1. In 1959 Lejeune, 
Gautier and Turpin discovered the relation between DS and the triplication of chromosome 212.
The diagnosis of DS is made by chromosome analysis, which can be initiated prenatally or postna-
tally based on the characteristic appearance of the newborn child. 
Down syndrome is in 95% of the cases caused by the presence of an entire extra copy of chromo-
some 21. A small number, 4% of the cases, have a partial trisomy, resulting from a translocation, 
and the attachment of an extra long arm of chromosome 21 to chromosome 14, 21 or 22. These 
infrequent cases have allowed the definition of the Down Syndrome Critical Region (DSCR) of 
chromosome 21 within the q22 region (about 5.4Mb in length)3 that includes a subset of genes 
that, when present in three copies, results in the major phenotypic features of DS, including the 
characteristic facial appearance, congenital heart disease, and intellectual disability4. Less than 1% 
of the cases are caused by mosaicisme, where some, but not all cells are trisomic. 
The presence of an extra chromosome 21 makes DS a biologically complex disorder. Sequencing 
of human chromosome 21 has been completed and almost 300 genes have been identified and 
are publically available5. Overexpression of any one of these genes can influence the development 
of DS in itself but these gene products can also interact with each other and with genes on other 
chromosomes. Recent evidence has shown that gene overexpression in persons with DS can be 
specific for tissue type6. Different subsets of chromosome 21 genes are over-expressed in different 
cell types.
The more than 80 clinical features, characterising the phenotype of DS, can vary in number and 
in severity, and none of the features diagnosed in DS is unique to persons with trisomy 217-9. 
Common DS phenotypes include intellectual disability and dysmorphic features involving the 
craniofacial area, neck and limbs. Manifestations include brachycephaly, epicanthal folds, flat nasal 
bridge, folded or dysplastic ears, open mouth, narrow palate, protruding tongue, short and broad 
hands, incurved fifth finger, transverse palmar lines, gap between the first and second toe, and hy-
perflexibility. Other clinical manifestations include cardiac malformations, thyroid dysfunctions, 
digestive system abnormalities, and seizures. There is also high susceptibility to leukaemia’s and 
infections10. Most males with DS are infertile. Although not sterile, women with DS show often 
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reproductive system dysfunction and an earlier menopause compared with women in the general 
population11.
None of the dysmorphic features is present in all cases, and no two persons with DS are the same, 
although the overall pattern is consistent and enables clinical recognition. There is an age-depen-
dant presentation of the phenotypic features. Some aspects are congenital, as there is hypotonia, 
others appear in childhood; such as growth retardation and development delay, and still others 
occur in adulthood or in the elderly e.g. premature aging and dementia. 
Three hypotheses have been singled out to explain the relationship between genotype and 
phenotype:
“The gene dosage effect” hypothesis proposes that dosage imbalance of specific genes on chro-1. 
mosome 21 causes specific DS phenotypes12,13. A restricted number of genes, located on the 
DSCR that are over-expressed due to the trisomy contribute to the phenotype.
Specific phenotypes arise from a small set of triplicated genes, but only when other genes (on 2. 
chromosome 21 or on other chromosomes) are also present and active14.
The “developmental instability” predicts that non-specific phenotypes result from genetic 3. 
imbalance and over-expression in combination with environmental interactions7,15. 
The use of models of DS in mice is one of the promising approaches to understanding the gen-
otype-phenotype relationship. The genes found on chromosome 21 are found on three mouse 
chromosomes; 16,17 and mouse chromosome 10 (see figure 1)10.
etiology
The majority of trisomy 21, or Down’s syndrome, is caused by the failure of chromosomes to sepa-
rate properly during meiosis. This process is also known as chromosome nondisjunction.
At least 90% of the cases of chromosome 21 nondisjunction are due to maternal meiotic errors 
during oogenesis.
Meiosis I is initiated in oocyte during fetal life, at about 11-12 weeks of gestation and, also after 
pairing, synapsis and recombination, arrests in prophase I until just prior to ovulation. At that 
time, the oocyte completes MI and progresses to metaphase II. Meiosis II extends over 3-4 days 
during ovulation period and is completed after fertilisation. Thus, homologous chromosomes are 
arrested in prophase I for 10 to 50 years.
It has been established that increased maternal age, the most significant risk factor for nondisjunc-
tion, is associated with errors occurring during oogenesis. For chromosome 21 nondisjunction, 
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advanced maternal age is associated with both maternal meiosis I and meiosis II errors16-18. The 
risk of having a child with DS increases with maternal age. While a 20 year old woman has a risk 
of 1/1400, the risk increases to 1/100 at the age of 40 years 18.
Paternal nondisjunction of chromosome 21 accounts for 5-10% of DS cases and is not associated 
with advanced paternal age. Spermatogenesis starts at puberty and cells entering meiosis move 
from one stage to the next without delay.
About 5% of cases of trisomy 21 are probably due to mitotic (postzygotic) nondisjunction of a 
chromosome 21 in the early embryo19. The mititotic errors are not associated with advanced ma-
ternal age.
Figure 1 Chromosome 21 in humans and in mice
Figure 1  
Chromosome 21 in humans and in mice 
 
APP: amyloid precursorprotein
SOD-1: super oxid dismutase
CSTB: Cystathionine β-synthase
S100B: S100 β
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Mosaicisme with a normal cell line occurs in about 2-4% of the cases. DNA polymorphism analysis 
in 17 families with mosaic trisomy 21 probands showed that the majority resulted from a trisomic 
zygote with mitotic loss of one chromosome20.
ePidemiology
In the Netherlands, data concerning incidence and life expectancy of persons with DS are not 
available. In Europe as a whole, DS accounts for 8% of all registered cases of congenital anomalies, 
with an estimated prevalence in the Netherlands of 10 to 14 per 10.000 live births21. The prevalence 
of DS among live births in the Netherlands, registered by the Dutch Paediatric Surveillance Unit in 
2003, 16 per 10.000 live births, was much higher than might have been expected based on previous 
registrations, and higher than suggested in literature21. The data from 2003 concerning terminated 
pregnancies reveals a total prevalence of DS (both live births and still births) of 26.8 per 10.000 
pregnancies22,23.
Worldwide the overall prevalence of DS is 10 per 10.000 live births, which seem to have increased 
in recent years. In countries in which abortion is illegal, such as Ireland and the United Arab Emir-
ates, prevalence is higher, varying from 17 to 31 per 10.000 live births. Conversely, the prevalence 
in France is low (7.5 DS per 10.000), due to high percentage (77%) of DS pregnancy termina-
tions24. In Europe, the proportion of mothers aged 36 and above has increased from 8% to 25% 
over the past 20 years24,25. Despite the availability of advanced prenatal screening tests, the influ-
ence of increasing maternal age outweighed the effect of antenatal diagnosis and termination of 
pregnancies.
Survival rates of children with DS continue to improve22,25,26. Infant survival after live birth is now 
close to 100%. This is partly due to better surgical management of gastrointestinal and cardiovas-
cular malformations. Exceeding expectations formed by previous literature27, the large majority 
of persons with DS are now expected to live into adult life. In 2000 the median life expectancy, in 
Australia, was 61.1 years for men and 57.8 years for women26.
In this respect, future studies should focus on probable changes in long term DS morbidity, as 
there is a growing cohort of survivors with DS, with their own specific health problems. Special 
attention is required for mobility, the presence of epilepsy, visual and hearing impairments and the 
development of Alzheimer’s disease.
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dementiA
The first English description of the link between DS and Alzheimer’s disease (AD) is found in a 
publication by Jervis in 194828, who described three persons with DS in their fourth decade whom 
were found to have intellectual deterioration, neuronal cell loss, senile plaques and neurofibril-
lary tangles. Present evidence suggests that persons with DS suffer exactly the same pathological 
process in later life as patients with AD in the general population29.
In DS, AD is assumed to be caused by the triplication and over-expression of the gene for amyloid 
precursor protein (APP), located on chromosome 21 and leading to the accumulation of cerebral 
β-amyloid30.The neuropathology of AD and some degree of the neuroanatomical changes associ-
ated with AD have been reported to occur in the brains of almost all persons with DS aged 40 
years and over30. However, clinical and epidemiological studies have shown that age-specific rates 
of AD among person with DS are lower than would be expected given the extensive amyloid and 
neurofibrillary pathology that is found at autopsy31,32. Even at ages associated with extensive neu-
ropathology, a proportion of elderly persons with DS remain functionally unimpaired.
In persons with DS, the average age of onset of dementia ranges from 38 to 70 years, with most 
cases occurring between 50 and 55 years of age. The prevalence of clinical AD has been examined 
for several decades31-52. Prevalence rates have varied from 4% in a community sample53 to 88% in 
an institution- based sample42. All studies showed an exponential increase in prevalence with age. 
Although triplication of the gene for APP may act to increase deposition of amyloid β in diffuse 
plaques in persons with DS, explanations other than increased APP alone are needed to account 
for the wide range in age at onset of the clinical signs of AD. 
Age
The factor that has been conclusively linked to an increase in risk for AD in DS is increasing 
age54. All studies showed an exponential increase in prevalence with age40,43,47-49,51,52,55-59. There is 
an ongoing debate on the percentage of DS persons that will eventually develop dementia if they 
reach a very old age. Several studies, mostly neuropathological, suggested that all patients develop 
AD31,60-63. Further research is required to investigate the age associated prevalence and incidence 
of dementia in persons with DS.
There are at least 10 known chromosome 21 genes that are involved in brain structure and func-
tion, but only 3 have been implicated in the neuropathology of DS64. These are the genes for amy-
loid β precursor protein (APP), for superoxide dismutase (SOD1), and for the astrocyte-derived 
neurotrophic factor S100β4,65,66 (see figure 1).
Chapter 1.1
20
Amyloid precursor protein (APP)
From a genetic perspective, Alzheimer disease (AD) is almost unavoidable in DS. In 1987, the gene 
that encodes the precursor protein of amyloid β was found to be located on chromosome 2167,68. 
Triplication of the gene for APP is not necessary for the development of phenotypic characteris-
tics of DS, but does seem necessary for the development of AD in persons with DS12,64. Prasher69 
described in a case report, a 78 year old woman with an appearance suggestive of DS, with partial 
trisomy 21 that included the genes for SOD-1 and S100β but did not include the APP gene. This 
woman showed neither dementia nor significant AD pathology. She had only two copies of the 
gene for APP, suggesting that triplication of this gene is necessary for the development of AD in 
DS.
superoxide dismutase (sod-1)
Oxidative stress is caused by an imbalance between the production of reactive oxygen and the 
biological system’s ability to detoxify the reactive intermediates or repair the resulting damage. 
Oxidative damage is considered to be a causal factor in the brain changes seen in AD within the 
general population. As a factor in the pathogenesis of AD in DS, the role of superoxide dismutase 
(SOD-1)65 may be relevant. The free radical, superoxide O2-, is converted to hydrogen peroxide 
(H2O2) by superoxide dismutase. Hydrogen peroxide is then detoxified by the enzymes catalase 
and glutathione peroxidase. Overexpression of SOD-1 has been found in all tissues including the 
foetal brain in DS70. Although SOD-1 may be an important component in the mechanism of pro-
tection against free radicals, it can also have a negative effect. It is possible that in DS, increase 
SOD-1 activity results in the overproduction of H2O2 and hydroxyl radicals which compromise 
cellular functioning in the brain, contributing to neurodegeneration54,71,72.
s100 β
S100 β, is a small, soluble, astrocyte derived protein, which is encoded by a gene mapped in the 
Down’s Syndrome Critical Region. It has trophic effects on neurons including proliferation and 
differentiation. In addition to these trophic effects, S100β has potentially neurotoxic effects at 
higher concentrations64. S100 β induces astrocytic expression of nitric oxide synthase with release 
of nitric oxide (NO). S100 β is overexpressed by activated astrocytes, associated with the amyloid 
plaques of AD and tissue levels of biologically active S100 β are markedly increased in the brain 
of AD patients.
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In persons with DS, S100 β expression, is elevated in the brain even at fetal stage, making 
S100 β-overexpression one of the earliest Alzheimer-associated brain alterations. This S100 
β-overexpression increases progressively throughout life in persons with DS73,74 and the degree of 
this S100 β-overexpression correlates with the degree of amyloid deposition in brain.
Apolipoprotein e (APoe)
It is well established that one of the major risk factors for the development of AD in the general 
population, is the presence of the allele ε4 of the Apolipoprotein E (APOE) on chromosome 1975,76. 
APOE is involved in cholesterol transport and lipid metabolism in plasma and is associated with 
greater accumulation of beta-amyloid in the brains of the elderly in the general population12,77,78. 
Numerous studies have shown that the presence of the ε4 allele is associated with early onset of 
AD, whereas the presence of the ε2 allele is associated with a delay in disease onset and is possibly 
protective79,80.
In persons with DS, the ε4 allele is associated with a 1.6 to 2-fold increased risk of AD and is as-
sociated with an early onset of the disease. The relation between APOE ε2 and the risk and onset 
of AD has been a controversial issue50,81-84.
estrogen 
In women who are pre-menopausal, estrogen promotes the growth, prolongs survival of cholin-
ergic neurons and has antioxidant properties. Women with DS appear to have an earlier age at 
menopause than women in the general population11,85-87. It is hypothesised that the earlier meno-
pause, including the reduction in estrogens following menopause, contributes to the earlier onset 
and increased risk of Alzheimer’s Dementia (AD) in women with DS88.
Pre-existing levels of cognitive ability
An explanation for the variability in age of onset and prevalence rates of AD in persons with DS 
may be found in the level of intellectual disability prior to the onset of neuropathological changes54. 
The reserve capacity model implicates that persons with DS with severe and profound intellectual 
disability should have a higher risk of AD than those with mild and moderate intellectual dis-
ability. In order to establish a diagnosis of dementia, a key criterion is that there is a decline in 
cognitive functioning from a person’s baseline level. The measurements have to be sensitive and 
the changes measured should be greater than found in normal aging44,89,90. The presence of severe 
and profound pre-morbid intellectual disability in persons may make additional cognitive deficits 
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associated with early stages of dementia difficult to detect. The existing literature on AD in DS in 
relation to pre-morbid intellectual disability, so far, is inconclusive42,51,59,91,92.
PeriPherAl biochemicAl mArkers in Persons with down’s syndrome
It has become clear that amino acids are not only essential for various metabolic pathways such 
as the synthesis of the major neurotransmitters, but also for maintenance of cell structure and 
functionality of many organs. In addition, amino acids are involved in immune responses93,94.
Over the past decade, several studies have shown that serum amino acid concentrations in persons 
with DS differ from concentrations in healthy controls95-97. At this moment, little is known about 
DS-specific biochemical pathways that are thought to be related to accelerated aging, to increased 
susceptibility to infectious diseases, to autoimmune disorders and to the development of AD.
cystathionine β-synthase
The gene encoded for the enzyme Cystathionine β-synthase (CBS) is located on chromosome 21 
(21q22.3)(see figure 1) and is overexpressed in persons with DS. CBS catalyses the conversion of 
homocysteine and serine into the dipeptide cystathionine. It shunts homocysteine away from the 
methionine cycle to the transsulfuration pathway resulting in the synthesis of cysteine and gluta-
thione. An increase in the transsulfuration, due to CBS overexpression, reduces the methionine 
synthase activity and results in lower conversion of 5-methyltetrahydrofolate to tetrahydrofolate 
(THF). This is the metabolically active form of folate, required for the novo synthesis of nucleotides 
for RNA and DNA synthesis. With respect to the CBS-related parameters, plasma concentrations 
of amino acids measured in persons with DS are in accordance with an overexpression of the CBS 
gene95,97,98.
nitric oxide
A growing body of evidence indicates that there is an increased oxidative stress in AD brains and 
it is hypothesised that nitric oxide (NO) can be related to many of the pathophysiological mecha-
nisms of AD99,100. The presence of any stimulant that leads to an overproduction of NO will probably 
cause neuronal damage101. The biologically active molecule NO is formed during the conversion of 
L-arginine to L-citrulline, a reaction catalysed by the enzyme nitric oxide synthase. In this process 
tetrahydrobiopterin (BH4) is the necessary cofactor. The ratio of the plasma concentrations of citrul-
line (Cit) and arginine (Arg), the so-called Cit-Arg ratio, is regarded as an index of NO synthesis102. 
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Brain inflammation is mainly caused by activation of micro-glia cells that produce a variety of 
pro-inflammatory and neurotoxic factors, including free radicals such as NO103,104. Inflammation 
and immune system activation are considered to play an important role in the development and 
progression of dementia105. 
neopterin
A marker of cell-mediated immune activation is the pteridine neopterin106. Neopterin is formed 
as a bypass product in the synthesis of BH4, which is a cofactor required for the biosynthesis of 
catecholamines, serotonin, and nitric oxide (see figure 2).
Monocytes and macrophages produce neopterin upon stimulation by interferon (IFN) γ106. Neop-
terin, besides being a marker of IFN activity, induces and enhances cytotoxicity and is a proin-
flammatory mediator. Higher levels of neopterin have been found in patients with inflammatory 
diseases of the central nervous system, infectious diseases, and tumours107.
Peripheral levels of neopterin increase with age. Recent studies showed higher levels of neopterin 
in persons with DS with and without AD95,108 .
Figure 2 Bio synthesis of pterins and biogenic amines.
Figure 2 
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scoPe of this thesis
The aim of the present longitudinal population based study on persons with Down’s syndrome 
(DS), aged 45 years and older is to study determinants of dementia and mortality, and to obtain 
new insights into biological pathways involved in the development of dementia in DS.
An overview of the study design, population characteristics and the instruments used is presented 
in chapter 2.1. The large number of subjects included in the study enables us to give more precise 
age-specific estimates for the prevalence and incidence of dementia and mortality. 
Apolipoprotein E (APOE), especially the APOEε4 allele, is consistently associated with dementia 
in the general population. Findings on the role of this gene in persons with DS are inconclusive. In 
chapter 2.2 we describe the effects of APOE on mortality and dementia in our study population of 
persons with DS (n=425), demented and non-demented. In a meta-analysis, we also compare our 
findings with those of the existing literature, focusing on the effect in elderly DS persons. Although 
life expectancy increases enormously, our knowledge of factors that influence survival in older 
persons with DS is still very limited. In Chapter 2.3 the impact of cognitive and functional decline, 
and physical comorbidity, on mortality risk in the course of time is examined. DS is considered as 
a model of precocious aging and of Alzheimer’s disease (AD). In Chapter 2.4, as an indication of 
this precocious aging in women with DS, the early menopause is described and related to survival 
and age at diagnosis of dementia.
Chapter 3 focuses on biochemical pathways possibly involved in the development of dementia in 
persons with DS. In chapter 3.1, first we describe peripheral biochemical parameters that reflect 
changes in homocysteine metabolism, immune function and monoaminergic neurotransmission 
in a small group of relatively healthy persons with DS aged 45 years and older. The study group 
comprised 48 persons with DS, without signs of dementia, psychiatric or somatic comorbidity and 
free of medication and was compared with 48 age and sex matched healthy controls. 
Among the various pathophysiological mechanisms involved in dementia in the general popula-
tion, inflammation and immune system activation are considered to play an important role in 
the development and progression of dementia. In Chapter 3.2, we present whether the plasma 
neopterin level, a marker for cell mediated immune activation and inflammation, is associated 
with an increased risk of dementia in persons with Down syndrome. 
In Chapter 3.3 we focus on the spectrum of amino acids and the role of Nitric Oxide (NO) and 
Branched Chain Amino Acids (BCAA) in our study cohort of persons with DS with and without 
dementia. Special attention was given to those amino acids, involved in the oxidative processes, 
and their relation to the development of Alzheimer dementia.
The findings of this study are summarized and discussed in light of the literature in chapter 4.
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AbstrAct
Numerous studies have documented that persons with Down’s syndrome (DS) are at an increased 
risk of Alzheimer’s disease (AD). However, at present it is still not clear whether or not all persons 
with DS will develop dementia as they reach old age.
We studied 506 people with DS, aged 45 years and above. A standardized assessment of cognitive, 
functional, and physical status was repeated annually. If deterioration occurred, the patients were 
examined and the differential diagnosis of dementia was made according to the revised Dutch 
consensus protocol and according to the ICD-10 Symptom Checklist for Mental Disorders. We 
compared our findings with those reported in the literature.
The overall prevalence of dementia was 16.8%. Up to the age of 60, the prevalence of dementia 
doubled with each 5-year interval. Up to the age of 49, the prevalence is 8.9%, from 50 to 54 it is 
17.7%, and from 55 to 59 it is 32.1%. In the age category of 60 and above, there is a small decrease 
in prevalence of dementia to 25.6%. The lack of increase after the age of 60 may be explained by 
the increased mortality among elderly demented DS patients (44.4%) in comparison with non-
demented patients (10.7%) who we observed during a 3.3-year follow-up. There was no decrease in 
incidence of dementia in the age group of 60 and above. Our findings are very similar to those pub-
lished in the literature. Patients with dementia were more frequently treated with anti-epileptic, 
anti-psychotic and anti-depressant drugs. The history of depression was strongly associated with 
dementia.
Our study is one of the largest population-based studies to date. We found that despite the expo-
nential increase in prevalence with age, the prevalence of dementia in the oldest persons with DS 
was not higher than 25.6%.
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introduction
Down’s syndrome (DS) is the most common cause of intellectual disability (ID). The syndrome is 
clinically characterised by congenital malformations, especially of the heart and the gastrointes-
tinal tract, which result in high mortality rates early in life. As a result of many improvements in 
the medical treatment of people with DS, the survival rate has increased in comparison with the 
past. Estimates of life expectancy suggest that about 44% of persons with DS will reach the age of 
60 and 14% will reach the age of 681. At present, Alzheimer’s disease (AD) appears to be the most 
important cause of morbidity and mortality among elderly DS persons. The neuropathology of AD 
includes the deposition of extra cellular beta-amyloid (Aß) in neuritic plaques and intracellular 
accumulation of neurofibrillary tangles. The neuropathological manifestations of AD in DS have 
been attributed to triplication and over-expression of the gene encoding for the ß-amyloid precur-
sor protein (APP), located on chromosome 21.
The prevalence, of clinical AD, has been examined extensively2-23. The average age at the onset of 
dementia was found to be between 50 and 55 years, with a range from 38 to 70 years. Prevalence 
rates have varied from 4% in a community sample24 to 88% in an institution-based sample12. Previ-
ous studies varied considerably in the populations studied, in the design of the study, and in the 
size of the population studied. Studies conducted with institutionalized patients may have been 
biased in that they included a selection of more severely intellectually disabled or demented pa-
tients. The advantage of a population-based study, including persons living in a community setting 
as well as institutionalized persons, is that there is no selection. Another major limitation of the 
previously listed studies is their small size, varying from 50 to 307 subjects. In particular, there 
were only small numbers of elderly DS persons included, which will have limited the interpreta-
tion and analysis of the prevalence of AD. This may also explain the diversity in the findings. At 
present it is still not clear whether or not all persons with DS will eventually develop dementia as 
they reach old age.
In this paper, we report on a study of a population-based series of 506 patients with DS. This is 
the largest study conducted that includes those with DS who are institutionalized as well as those 
living in the community. The large size of the study enables us to give more precise age-specific 
estimates for the prevalence and incidence of dementia. All patients were physically examined and 
screened for dementia and followed over the years up to their deaths. We studied the prevalence 
and incidence of dementia as well as mortality in the demented and the non-demented. We com-
pared the prevalence of dementia with that reported in the existing literature.
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study population
In the south and southwest of the Netherlands, including the regions Rotterdam, Zeeland, Noord 
Brabant and Gelderland, all organizations involved in the care of intellectually disabled persons 
were invited to participate in this longitudinal study. Their administration departments and gen-
eral practitioners were asked to recruit all those who had been diagnosed with DS and were aged 
45 years and above. Only subjects in whom the diagnosis was not established were not covered by 
the study. Thus, the sample from these regions represents almost all the DS persons living in the 
community, as well as those living in institutions. The recruitment period was from 1 December 
1999 to 1 December 2003.
Ethical approval for this study was obtained from the medical ethical committee of the Erasmus 
Medical Center. The medical ethical committees and committees consisting of relatives of DS per-
sons residing in local institutions and organizations also approved the protocol.
Of the invited organizations, 75% (21/28) participated in the study. Reasons for not participat-
ing were: ethical problems with the study of intellectually disabled people (one organization) 
and increased workload for the nursing staff (six organizations). Permission for individuals to 
participate in the study was obtained with the help of the general practitioner or the medical of-
ficer responsible for the individual’s medical care. Written informed consent to participate, and to 
provide blood samples, was also obtained from legal representatives (relatives and/or carers), after 
written information was provided. Written consent was also obtained from persons with DS who 
had the mental capacity to consent, after being given an explanation. The response rate in those 
organizations that participated is estimated to be 75%, based on a retrospective report. Due to the 
recruitment procedure and issues of consent, information was not available on non-responders.
All participants included in the study received a complete assessment at the baseline, including a 
home interview with a relative, an interview with carers and a clinical examination. Blood was taken 
from all participants. A standardized assessment of cognitive and functional status was repeated 
annually. In the event of death, permission to perform an autopsy on the brain was requested.
medical records
For this study, the diagnosis of DS was re-evaluated based on clinical characteristics according to 
the criteria described by Roizen et al25. In 283 persons (56%) the clinical diagnosis was confirmed 
by available cytogenetic characterization. Of these persons, 271 (53.6%) had complete trisomy 21, 
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5 (1%) had a translocation of chromosome 21 and 7 (1.4%) had a mosaic form. Chromosomal 
analysis was not available for the remaining 223 people (44%).
Results of (pre-morbid) intelligence tests and previous levels of functioning were studied by a 
review of medical records. Severity of ID was classified using the International Classification of 
Diseases (ICD-10) criteria26. The general practitioner was asked to provide information about cur-
rent medical and psychiatric disorders and current drug use.
The participant’s medical records were reviewed to confirm the possible existence of past or pres-
ent disorders. Special attention was given to psychiatric disorders, cardiovascular and cerebro-
vascular diseases, hypertension, thyroid disease, diabetes, sensory impairments, neoplasm and 
epilepsy. The use of non-steroidal anti-inflammatory drugs, estrogens and psychiatric drugs was 
also reviewed.
Physical examination
A comprehensive physical examination was performed at the baseline and among those who ful-
filled the dementia criteria during the follow-up screening. The physical examination included 
measurement of height and weight and an assessment of sensory impairment (vision and hearing). 
A picture-graded test, the Teller acuity card, was used to assess visual acuity and distraction27, and 
simple speech and whisper tests were conducted to screen hearing ability. Cardiovascular screen-
ing involved an electrocardiogram and measurements of systolic and diastolic blood pressure on 
both arms and legs in a lying position. The neurological examination was aimed at establishing 
gross and fine motor impairments, mental status, and the presence of pathological or asymmetric 
reflexes, and neurological signs such as myoclonus, ataxia, and Parkinsonism.
interview
Each participant was evaluated using a semi-structured interview with his or her primary carer, 
sometimes a family member, but generally a professional carer. The interviewee had to have known 
the participant for a minimum of 6 months. Smoking habits, alcohol use, diet, mobility and gen-
eral mental functioning were recorded. This interview was supplemented with the Vineland Adap-
tive Behavior Scales28, the Dementia Questionnaire for persons with an ID (DMR)29, 30, a Dutch 
social competence rating scale for intellectually disabled people (“Sociale Redzaamheidsschaal”) 
(SRZ))31, and the Reisberg Functional Assessment Staging Tool32.
To obtain information on past physical status and mental ability of the participant, first-line rela-
tives were asked to provide information about the history of development. First-line relatives were 
also required to provide the family history of physical and psychiatric disorders.
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laboratory examination
The laboratory examination consisted of plasma screening for hematological, biochemical, and 
thyroid functions. DNA was isolated. Plasma and serum were stored at -80ºC for future research. 
diagnosis of dementia  
Baseline
At the baseline, the first-line relative, the primary carer and the general practitioner had to answer 
the question: has this patient been suffering from dementia for at least six months, yes or no? If 
only one interviewee did not respond affirmatively, the patient was not included as being a pos-
sible sufferer of prevalent dementia. For those who were included, the presence of dementia was 
subsequently determined by the research physician (A.C.), by means of a medical examination, 
according to a standardized protocol. Those participants who suffered from medical, psychiatric 
and neurological or laboratory conditions other than AD, potentially causing cognitive decline, 
were examined in detail to establish whether these conditions caused the deterioration. If this was 
the case, the participants were excluded from the group of demented persons. 
The diagnosis is based on the ICD-10 Symptom Checklist for Mental Disorders33, in particular, de-
mentia in Alzheimer’s disease26 and the guidelines produced by an international consensus panel 
established under the auspices of the Ageing Special Interest Group of the International Associa-
tion for the Scientific Study of Intellectual Disabilities (IASSID)34, 35.
Follow up
All those participants who were demented (n = 85), as well as those who were not identified by 
interviewees as (possibly) being demented at the baseline, were monitored until they either died 
or censored (i.e. withdrawn from the study by their representatives, n = 3). The annual screening 
consisted of an extensive screening examination (DVZ, SRZ and clinical data). At present, there 
were 103 persons followed up for 1 year; 130 for 2 years; 160 for 3 years; 76 for 4 years; 30 for 5 
years and 10 persons died within 1 year. Those who fulfilled the dementia criteria are followed 
more intensively at 6-month intervals. The examination for this group included a screening tool 
to assess functional, social and cognitive decline, as well as a clinical work-up, based on a medical 
examination to exclude other physical and psychiatric factors as the cause of decline. Finally, all 
patients were diagnosed according to the same protocol as the prevalent patients. All new diagno-
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ses have been discussed in a diagnostic panel consisting of members of the reference group with 
expertise in the field of ID (A.M.W.C., G-J.V., F.E.V., H.M.E. and C.M.vD.). 
Screening tools for the assessment of functional, social, and cognitive decline
Participants were followed longitudinally for clinical signs of dementia, using a number of screen-
ing tools. These included clinical data, the DMR, the social competence rating scale for intellectu-
ally disabled people (also known as SRZ), and the Reisberg Functional Assessment Staging Tool.
The DMR30 is a 50 item questionnaire, divided into two types of scores: cognitive and social. The 
cognitive scores relate to the following domains: short-term memory, long-term memory, and spa-
tial and temporal orientation. The social scores relate to: speech, practical skills, mood, activity and 
interest, and behavioural disturbance. To screen for patients with dementia, we identified those 
with an increase in the cognitive score of >7 (SCS>7) and/or an increase in the social score of >5 
(SOS>5). An increase in either or both scores was taken to indicate a possible deterioration in de-
mentia (either deterioration in already established dementia or the first indication of dementia).
The social competence rating scale for intellectually disabled people (SRZ)31, which covers aspects 
such as: the ability to define and execute tasks for themselves, social skills, daily living skills and 
the effective use of language, was determined by 31 items (a maximum 4 per item). A decrease in 
the score of 25% was used to screen for those with a definitive decline.
statistical analysis   
Data were analysed using chi-square tests for categorical variables and one-way analysis of vari-
ance (ANOVA) for continuous variables. Logistic regression analysis was used to study the rela-
tion between mortality and age, sex and dementia status. Statistical significance was defined at a 
significance level of 5%.
results
Characteristics of the study population are presented in Table 1. The participants comprised 506 
adults with DS, of whom 304 were men (60.1%) and 202 were women (39.9%). The mean age of the 
men was 51.9 years (standard deviation (SD) = 5.1, range: 45 to 77). The mean age of the women 
was 52.0 years (SD = 5.4, range: 45 to 77). Most of our participants, 319 (63%) lived in institutions 
or in homes connected with institutions, 11(2.2%) still lived with their parents, and 176 (34.8%) 
were living in (supervised) community units.
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According to ICD-10 criteria, 150 of the participants (29.6%) had a severe to profound level of ID, 
154 (30.4%) a moderate level, and 21 (4.2%) a mild level of ID. The severity of ID was not known 
for 181 participants (35.8%).
The overall prevalence of dementia was 16.8% (85 cases) (95% confidence interval (CI) = 16-23%). 
There was no significant difference between men (16.4%) and women (17.3%). The persons with 
dementia were significantly older, (ANOVA, F = 21.5, d.f. = 1, p<0.001), [n = 85, mean age 54.5 
years ± 5.5 (SD)] than the non-demented [n = 421, mean age 51.4 years ± 5.0 (SD)]. There is 
no difference in the pre-morbid cognitive level between the persons with dementia and those 
without dementia. Persons with dementia were more often institutionalized (χ² = 5.37, d.f. = 1, p 
= 0.02), dementia may be a reason for institutionalization. The demented persons also were more 
frequently treated with anti-epileptic (χ ² = 26.09, d.f. = 3, p<0.001) and anti-psychotic drugs (χ² = 
19.34, d.f. = 3, p<0.001). Patients with depression and dementia were followed specially to exclude 
a misdiagnosis of dementia due to depression. There is a relation between a history of depression 
and dementia (χ² = 11.22, d.f. = 3, p = 0.01) and the use of anti-depressant drugs (χ² = 15.4, d.f. = 
3, p = 0.002). Sensory problems were not associated with dementia in this study population.
Figure 1 shows that up to the age of 59 years, the prevalence of dementia doubled with each 5-year 
interval. Up to the age of 49, the prevalence is 8.9% (95% CI = 5-12%), from the age of 50-54, 17.7% 
(95%CI = 12-23%) and from the age of 55-59, it is 32.1% (95%CI = 22-42%). After the age of 60, we 
did not find a further increase in the prevalence of dementia 25.6% (95% CI = 12-40%). 
Table 1 General characteristics of the participants with and without dementia at baseline
Dementia
All absent present
Population size 506 421((83.2%) 85(16.8%)
Gender
Women 202 167(39.7%) 35(41.2%)
Men 304 254(60.3%) 50(58.8%)
Age (years)* 51.9(6.2) 51.4(5.0) 54.5(5.5)
Living
Community 187 165(39.2%) 22(25.8%)
Institutionalised 319 256(60.8%) 63(74.2%)
Depression
Past 115 84(19.9%) 31(36.4%)
Present 20 15(3.6%) 5(5.8%)
Antidepressive drug 46 30(7.1%) 16(18.8%)
Visual loss 277 224(53.2%) 53(62.3%)
Hearing loss 203 169(40.1%) 34(40%)
Use of psychotropic drug 76 51(12.1%) 25(29.4%)
*values are means (standard deviation)
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Up to the age of 59, the prevalence observed in this study is similar to that of the other studies. The 
study of Franceschi is an exception in that the prevalence of dementia is substantially higher at all 
ages. As can be seen in figure 2, the prevalence increases with age in all other studies. There are 
only two studies that included persons older than 65 year19, 36. In one (Visser et al.)19, the prevalence 
increased to 100%, and in the other (Tyrell et al)36, the prevalence peaks at 50%. In contrast with 
the findings of our study there is no levelling off after the age of 60 in these studies. However, other 
studies also show a deviation from the exponential increase in prevalence (Lai 1989, Schupf 1989, 
Haveman 1994), as can be seen in table 2 and figure 2.
There may be two explanations for the observed decrease in prevalence in our study. The incidence 
of dementia may decline in those aged 60 and above. Alternatively, the mortality rate may be 
increased in those with dementia after or before the age of 60 years. The possibility of a decrease in 
the incidence of dementia was evaluated by studying the incidence of dementia in each age group, 
per 100 person years, on the basis of follow-up screening of the non-demented group (followed up 
to 1 July 2005). The largest increase in incidence was seen in the age group of 60 and above (Table 
3). The second possibility, an increased mortality in those with dementia, was studied using our 
follow-up data. After a follow-up with a mean time of 3.3 years (minimum 0.0; maximum 6.1), 81 
(16%) participants had died, and 36 (44%) of these were diagnosed with dementia at the baseline. 
In a logistic regression analysis, mortality was significantly related to age and the dementia status 
(p<0.001). In all the age categories, through to 60, the mortality of those with dementia is more 
than twice that of those not suffering from dementia (figure 3). 
Figure 1 Prevalence of dementia in 506 persons with Down’s syndrome in the Netherlands by living situation
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Table 2 Age-related prevalence of dementia in Down’s syndrome
Authors Sample Residence Criteria
Lai & Williams (1989) 53 DS Institution Functional decline
Schupf et al (1989) 99DS
and controls
Institution
Community
Regression
Franceschi, et al (1990) 50 DS Community NINCDS/ADRDA
Haveman et al (1994) 307 DS
and 1274 controls
Institution
Community
Diagnosis of dementia
made by physician
Prasher (1995) 201 DS Institution
Community
DCR 10
Johannsen et al (1996) 72 DS Community Clinical criteria
Visser et al (1997) 307 DS Institution Clinical signs 
Cognitive performance
EEG
Sekijima et al (1998) 106 DS Institution Clinical characteristics
CT scanning
Oliver et al (1998) 57 DS Community Cognitive deterioration
Holland et al (1998) 75 DS Community
Institution
Camdex
Tyrell et al (2001) 285 DS Community DSMIV
This study 506 DS Community DSM IV
ICD 10
CT, computed tomography; DCR, Diagnostic Criteria for Research; DSM, Diagnostic and Statistical Manual of Mental 
disorder; EEG, electroencephalogram; ICD, International Classification of Disease; NINCDS/ADRDA, National Institute of 
Neurological and Communicative Disorders and Stroke - Alzheimer’s Disease and Related Disorders Association.
Figure 2 literature overview of studies of the prevalence (%) of dementia
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discussion
The prevalence of dementia in our population of persons with DS increased from 8.9% in the age 
category of 45-49 years to 32.1% in the age category of 55 to 59 years, but did not increase over the 
age of 60 years. In contrast, the incidence of dementia did increase, also after the age of 60 years. 
The incidence increased from 2.53 per 100 person years in the age category of 45-49 years, to 13.31 
per 100 person years in the oldest age category.
Before interpreting the findings, an issue to be discussed is the validity of the diagnosis. Although 
there are now well-accepted criteria for the diagnosis of dementia in adults with ID34, 35, which 
we have used, the diagnosis of dementia remains difficult, both in research setting and in clinical 
practice. For the present study, persons were systematically screened for dementia and examined 
in person. The demented patients in this study met the ICD-10 criteria and had an insidious and 
progressive course of the disease. Also, special attention was given to the exclusion criteria for 
Figure 3 Mortality after 3.3 years (mean) of follow up in 506 persons with Down’s syndrome in the 
Netherlands
Figure 3 
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Table 3 Incidence of dementia per 100 person years in Down’s syndrome
Age Total follow-up
years (01-07-2005)
Number incidence Incidence per 100
Person years
< 50 709.39 18 2.53
50-54 495.79 14 2.82
55-59 163.73 8 4.88
>60 67.59 9 13.31
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conditions such as depression, hypothyroid disease, infection, and visual and hearing loss. If there 
was no evidence from the history, physical examination, or special investigations for any other 
possible cause of dementia, the differential diagnosis of AD of the prevalent cases was made by a 
research physician (AMWC), with 15 years experience in the care of patients with ID.
Also related to the validity of the diagnosis is the problem that there is an overlap between the 
symptoms of depression and AD. Typical symptoms of depression in persons with DS, such as 
apathy and inactivity, loss of self-help skills and even loss of speech, can also be observed in AD37, 
38. The overall reported prevalence rate of depression in DS varies widely from 2%39 to 5%40 to 
11.3%41. In our study we found a prevalence of 22.7%, which concerned 115 DS persons. This his-
tory of depression is strongly associated with AD, as is also the use of anti-depressant drugs. The 
high prevalence of depression in our study and its association with dementia raises the question 
whether the demented patients with depression are misdiagnosed. However, we followed all pa-
tients with dementia for more than one year. It is extremely unlikely that patients with depression 
without a true dementia would not have improved during this period of follow-up. This makes it 
unlikely that misdiagnosis explains the high prevalence of depression in demented patients in our 
study.
Other factors that can contribute to the errors in the differential diagnosis in persons with DS 
include the high occurrence of sensory disabilities. We found a very high prevalence of visual and 
hearing problems. However, these were not associated with dementia after examination by the 
research physician.
Returning to the results of our study, we found there were 85 (16.8%, 95%CI = 16-23%) patients 
with dementia in a sample of 506 DS people. This figure is higher than the 4.4% reported by De-
venny et al.24 and the 13.3% by Tyrrell et al36, but it is lower than the prevalence of 15-45% reported 
by Prasher et al.42. We found an increase in dementia cases up to the age of 59. These results were 
consistent with other population-based prevalence studies10, 13, 17, 19, 20, 22, 23, 36, 43-45. All studies showed 
an exponential increase in prevalence with age. There are important methodological differences 
that hamper direct comparison of studies. It is difficult to compare our study with those with only 
institutionalized persons as they may have been selected as a result of selection bias. Furthermore, 
the sample size of the previous listed studies is small. This concerns particularly the elderly DS 
persons. Despite these differences, most findings are similar, with one exception. In a community-
based study of adult patients with mild ID, Franceschi et al.13 reported very high prevalence rates, 
using the National Institute of Neurological and Communicative Disorders and Stroke - Alzheim-
er’s Disease and Related Disorders Association (NINCDS/ADRDA) criteria. These are the criteria 
normally used in the general population, which may explain this study deviates from others and 
ours. The highest prevalence figures reported were found in the study of Visser et al.19. Including 
307 institutionalized DS people; they found a prevalence of 100% in the age group of 70 years and 
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above. However, this finding is based on only two patients in this age category. Most studies in-
cluded institutionalized people, like the study of Visser et al.19 (see Table 2). Our population-based 
study clearly shows that the prevalence in those who are institutionalized is higher, suggesting 
hospitalized studies are susceptible to selection bias. 
In our population-based study, we found that despite the exponential increase in prevalence with 
age, the prevalence of dementia decreases in the oldest group and did not exceed 28.6%. The ob-
served decrease in prevalence cannot be explained by a decrease in incidence. In contrast, the larg-
est increase in incidence of AD was seen in the age group of 60 and above (Table 3). Alternatively, 
differences in mortality between demented and non-demented persons with DS may explain the 
decrease in prevalence. When comparing the mortality between demented and non-demented 
persons, the largest differences were found before the age of 60, being not significant after 60. 
Therefore, our results suggest that the high mortality in persons with dementia, up to the age of 
60, may explain partly our decrease in prevalence of dementia after the age of 60 years (see figure 
3). However, other factors also may contribute to the low prevalence after this age, which remain 
to be unraveling. Also remarkable is the finding that after the age of 60, the mortality in those who 
are demented, as well as those who are not demented, at baseline, is almost the same. These results 
suggest, that somatic and physical pathology appears to become more important than dementia as 
a cause of death after the age of 60 years. 
There is an ongoing debate on the percentage of DS persons that will eventually develop dementia 
in old age. Several studies, mostly neuropathological, suggested that all patients develop AD7, 46-49. 
Our study, including persons up to the age of 77, strongly argues against a full penetrance of 
AD. Further research is required to investigate the age-associated prevalence and incidence of 
dementia in persons with DS and the relation to morbidity and mortality. One of the major clinical 
implications of the fact that even with advanced age, not all persons with DS develop dementia, 
is the need to identify and treat reversible conditions. It will be interesting to see which factors 
predict the survival in this population-based study during a follow-up. Our study, among others, 
shows that dementia is a major problem in elderly persons with DS.
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AbstrAct
Apolipoprotein E (APOE) is consistently associated with dementia in the general population. 
Findings on the role of this gene in persons with Down’s syndrome (DS) are inconclusive. We 
studied the effects of APOE on mortality and dementia in a longitudinal prospective study of a 
large population-based sample of persons with DS (n=425), demented and non-demented. There 
was evidence that APOEε4 is correlated with the rate of decline in the social competence rating 
scale (SRZ) (p=0.04). In our population we found overall a modest but not statistical significant ef-
fect on the prevalence of dementia: Odds Ratio (OR): 1.57, (95% CI = 0.87-2.82). We did observed 
a significant long-term effect on the incidence of dementia: Hazard Ratio (HR): 4.66, (95%CI = 
1.35-16.14), but for those with a follow up less than 3 years the risk was not significantly increased: 
HR: 0.83, (95%CI = 0.35-1.94). When pooling our data in a meta-analysis, the APOEε4 allele 
shows a 1.59, (95%CI = 1.19-2.12) increase in risk of dementia in persons with DS. We conclude 
that APOE is influencing the risk of dementia in persons with DS.
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introduction
The increased risk of Alzheimer’s disease (AD) in people with Down’s syndrome (DS) is well 
known. In DS, AD is assumed to be caused by the triplication and over-expression of the gene 
for amyloid precursor protein (APP), located on chromosome 21 and leading to the accumula-
tion of cerebral β-amyloid1. However, there is a wide variation in risks and age at onset of AD in 
persons with DS, suggesting there are other factors modifying the disease onset2. In the general 
population, the apolipoprotein E (apoE: lipoprotein; APOE: gene) on chromosome 19 modulates 
the risk of AD in some studies3-5. The ε4 allele of APOE is associated with earlier age at the onset 
and increased risk of AD. On the contrary the APOE ε2 allele may reduce the risk of dementia in 
heterozygous carriers.
In persons with DS, a large variation of the APOE allele frequencies has been found6-8, most likely 
reflecting the different geographic origins. The relation between APOE ε4 and the risk and onset 
of AD has been controversial. Some studies showed an increased risk of AD associated with the 
APOE ε4 allele in persons with DS2, 9-12, but others could not confirm this7, 8, 13. There is evidence 
that APOE ε2 is associated with increased longevity in some studies of DS10, 14, 15, but a protective 
effect on AD15-17 could not be confirmed by all9. The APOE ε4 allele has been associated further 
with early mortality18, but a meta-analysis based on data from 538 persons with DS showed no 
significant evidence for an increased mortality of APOE ε4 homozygotes with DS19. From a bio-
chemical perspective, one may assume that APOE ε4 is involved in dementia through the amyloid 
pathway20, 21. APOE ε4 may interact with the amyloid-β (Aβ) peptide to increase Aβ aggregation. 
However, one also may assume that having three copies of APP may overwhelm the effect of the 
APOE ε4 on Aβ metabolism, making the APOE genotype less relevant for persons with DS in 
comparison to the general population.
The aims of the present study are to investigate the effect of the APOE ε4 allele on cognitive and 
functional decline and the risk of developing dementia in people with DS.
We also compared our findings with those of the existing literature, focusing on the effect in el-
derly DS persons. 
methods
study population
Participants are persons with DS, aged 45 years and older, who were enrolled from 1 December 
1999 until 1 December 2003 in a community-based study on DS and ageing in the Netherlands. 
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The sampling procedures for this study have been described in detail elsewhere22. In brief, we 
studied 506 people with DS of whom 304 were men (60.1%). For this study the diagnosis of DS was 
re-evaluated based on clinical characteristics according to the criteria described by Roizen et al23. 
In 283 cases (56%) the clinical diagnosis was confirmed by available cytogenetic characterisation. 
Of these persons 271 (53.6%) had complete trisomy, 5 (1%) had a translocation of chromosome 
21 and 7 (1.4%) had a mosaic form. Results of (premorbid) intelligence tests and previous level 
of functioning were studied by reviewing medical records. All participants received a complete 
assessment at the baseline. Blood was taken from the participants, when possible. Plasma and 
serum were stored at -80°C and DNA was isolated. In the event of death, permission to perform an 
autopsy on the brain was requested.
Ethical approval for this study was obtained from the medical ethical committee of the Erasmus 
Medical Center and the ethical committees consisting of relatives of DS persons residing in lo-
cal institutions and organisations. Written informed consent to participate, and to provide blood 
samples, was obtained from legal representatives (relatives and/or carers), after written informa-
tion was provided. Written consent was also obtained from persons with DS who had the mental 
capacity to consent.
clinical assessments
The persons in our study were assessed for Alzheimer’s disease using the ICD-1024 criteria and 
according to the guidelines produced by an international consensus panel established under the 
auspices of the Ageing Special Interest Group of the International Association for the Scientific 
Study of Intellectual Disabilities (IASSID)25. The diagnosis of dementia was supported using two 
observer-rated questionnaires, namely the Dementia Questionnaire for persons with an intellec-
tual disability (DMR)26, 27 and the Social Competence Rating Scale for persons with an intellectual 
disability (SRZ)28. Both questionnaires were used as screening instruments, to support a possible 
diagnosis of dementia, through detecting a decrease in function over time, as recommended by the 
Ageing Special Interest Group in 1997 (IASSID)25.
The Dementia Questionnaire for persons with an intellectual disability (DMR) is a 50-item ques-
tionnaire, separated into two types of scores: those related to cognitive function and those related 
to social skills. The cognitive scores relate to the following domains: short-term memory, long-term 
memory, and spatial and temporal orientation. The social scores relate to: speech, practical skills, 
mood, activity and interest, and behavioural disturbance. To screen for persons with dementia, we 
used a cut off, a worsening of cognitive scores of > 7 points and /or a worsening of social scores of 
> 5 points to ascertain suspect patients. The SRZ, the social competence rating scale for persons 
with an intellectual disability28, is a Dutch rating scale which covers aspects as social skills, daily 
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living skills and the effective use of language. A decrease in score of 10% and higher was used to 
screen for those who were suspect of developing dementia. 
Baseline 
At the baseline, the first line relative, the primary carer, and the general practitioner had to answer 
the question: ”Has this patient been suffering from dementia for at least six months?” If this diag-
nosis was also confirmed by the research physician (A.M.W.C.), by means of a medical examina-
tion, according to a standardized protocol22 based on ICD10 criteria, these patients were included 
in the group of demented persons at the baseline, as the prevalent cases.
The demented, as well as the non-demented, received a complete assessment at baseline that in-
cluded interviews with relatives, carers and the general practitioner. It also included a general 
physical and neurological examination. The medical reports were reviewed to examine past or 
present disorders and the possible use of drugs.
Follow up 
Participants that were not demented at baseline were screened annually. Those who fulfilled the 
dementia criteria, at baseline or during follow-up, were followed more intensively at 6-month in-
tervals. All new diagnoses were based on screening tools to assess functional, social and cognitive 
decline, as well as on a clinical work up, which was based on a medical examination to exclude 
other physical and psychiatric factors as the possible cause of decline. The screening tools used 
are the DMR, the SRZ, an interview with the primary carer and the general practitioner. All new 
diagnoses were discussed in a diagnostic panel consisting of members of the reference group with 
expertise in the field of intellectual disability (authors A.M.W.C., G-J.V., F.E.V. and H.M.E.). 
APoe genotyping
APOE genotypes were determined on 5ng/μl dry DNA samples using Taqman allelic discrimina-
tion technology29 on an ABI Prism 7900HT Sequence Detection System with SDS v 2.1 (Applied 
Biosystems, Foster City, CA). APOE genotyping was obtained blind to all clinical information.
meta-analysis
For the meta-analysis of the APOE allele frequency in DS persons, with and without dementia, we 
performed a computer search in PUB-MED for the period 1995-up to, and including July, 2005 
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using ‘APOE’ and ‘Down’s syndrome’ as search terms. We only included studies if the diagnostic 
criteria for AD were well described and met our criteria, and if the data presentation also made it 
possible to calculate the APOE allele frequencies for the demented as well as the non-demented 
persons. We try to include studies with a population age comparable with our study population. 
Our population has a relatively “old age” with subjects 45 years and older and with a mean age 
of 51.6 years. To broaden the number of studies available for analysis we included studies with a 
mean age of persons with DS of at least 40 years. 
statistics
Data were analysed using chi-square tests for categorical variables and one-way analysis of vari-
ance (ANOVA) for continuous variables, with Bonferroni correction for multiple testing, to detect 
if there was a difference in mean scores between the groups according to their level of intellectual 
disability. The independent T-test was used to compare the mean decrease in SRZ scores between 
the different genotypes. Odds ratios (OR) were using the ε3ε3 genotype as reference, with a 95% 
Confidence Interval (CI). Multiple logistic regression analysis was carried out to estimate the 
relative influence of risk factors as age, gender, level of intellectual disability and APOE on the 
development of AD. The Cox proportional hazards model was used for survival analysis, using 
age as the underlying time of the model. The analyses were done using the “counting” option 
implemented in the survival analysis method included in the S-Plus package (S-Plus, version 6.0). 
In the meta-analysis we used the Mantel Haenszel procedure, random effects model, (RevMan V. 
4.2) to compute the odds-ratios.
results
characteristics
From the 506 participants with DS, the APOE genotype was determined in 425 persons (84%), 
who consented to give blood. From the 425 persons 267 were men (62.8%). The mean age of men 
was 51.6 years (range 45-67), and for women 51.7 years (range 45-77). Severity of intellectual 
disability was classified using the International Classification of Diseases, 42.6% had a severe level 
(IQ<35); 50.0% had a moderate level (IQ 35-50) and 7.4% had a mild level of intellectual disability 
(IQ 50-70).
Of the total study population, 67 persons (15.8%) were diagnosed as having dementia at the base-
line and 60 persons died during follow-up (reference date 1 December 2005). After a mean time of 
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3.68 years of follow-up (minimum 0.08; maximum 6.48) there are 405 persons followed up for at 
least 1 year, 301 for 3 years, 182 for 4 years, and 8 for 6 years or more. 
APOE allele frequencies were comparable with the general Dutch population30: ε2ε2 n = 7(1.6%), 
ε2ε3 n = 59 (13.9%), ε2ε4 n = 18 (4.2%), ε3ε3 n = 243 (57.2%), ε3ε4 n = 88 (20.7%), ε4ε4 n = 10 
(2.4%). APOE genotypes and allele proportions were in Hardy Weinberg equilibrium. There is no 
significant difference in the mean follow-up time between the different allele groups: F (5) = 0.30, 
p = 0.91. Differences in allele frequency in ethnic groups may lead to spurious findings in genetic 
studies31. We have only two persons from non-Caucasian origin included in the study, both with 
ε3ε3 genotype, which makes it unlikely they will lead to biased findings.
Table 1 shows the proportion of APOE ε4 and APOE ε2 carriers by age and sex. The proportion 
of APOEε4 carriers decreased significantly (χ², p = 0.04) after the age of 60 years, suggesting that 
APOE ε4 carriers have an increased risk of mortality. We did not observe a significant difference 
by age category for the APOEε2 carriers. We also did not observe a significant difference when 
stratifying by gender.
There was no significant difference in the mean age at the baseline as a function of the APOEε4 
status: F (1) = 0.72, p = 0.39. Although the mean age at death for the APOEε4 carriers (55.8, SD 
4.2) was younger than the mean age for the non-carriers (58.7, SD 6.4), the difference was not sig-
nificant: F (1) = 3.02, p = 0.09. During the follow- up, there was no difference in mortality between 
the APOEε2 carriers and non–carriers: F (1) = 0.35, p = 0.55.
The association between APoe and cognitive and functional decline
We studied whether APOEε4 predicts cognitive and functional decline in the non-demented par-
ticipants of the study (n = 358). We analysed the proportion of persons who met the screening 
criteria, suspect for dementia, for DMR and SRZ, after one, two, and three assessments separately, 
after the baseline measurement. The mean follow-up time is 3.68 years (SD 1.36). Not all partici-
pants take part in all assessments at the reference date; December 1, 2005.
Table 1 Baseline characteristics by APOE carrier ship
Age (years) number gender men/
women
ε4 carriers ε4 noncarriers ε2 carriers ε2 noncarriers
< 50 189 119/70 52 (44.8) 137 (44.3) 35 (41.7) 154 (45.2)
50-54 147 91/56 41 (35.3) 106 (34.3) 33 (39.3) 114 (33.4)
55-59 63 43/20 20 (17.2) 43   (13.9) 12 (14.3) 51   (15.0)
> 60* 26 14/12 3   (2.6) 23   (7.4) 4   (4.8) 22   (6.5)
All 425 267/158 116 309 84 341
Values are n (%)
* p = 0.04
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As expected, the proportion of persons who met the criteria increased with time. For the DMR, 
the risk of meeting the screening criteria, as mentioned before, was not significantly related to the 
presence of the APOEε4 allele (figure 1a and 1b), neither according to the cognitive scores (SCS) 
nor according to the social scores (SOS). There was only one person, with two ε4 alleles, who met 
Figure 1a Decline according to the DMR/SCS criteria over time, by APOEε4 genotype
Figure 1a  
Decline according to the DMR/SCS criteria over tim , by APOEε4 genotype 
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DMR: The Dementia Questionnaire for persons with an intellectual disability
SCS: sum of cognitive scores
Figure 1b Decline according to the DMR/SOS criteria over time, by APOEε4 genotype
Figure 1b  
Decline according to the DMR/SOS criteria over time, by APOEε4 genotype 
 
 
 
  
0 
5 
10 
15 
20 
25 
30 
1 2 3
period after baseline
pe
rc
en
ta
ge
 w
ho
 fu
lfi
ll 
th
e 
cr
ite
ria
 
no APOE 4
one 
two 
DMR: The Dementia Questionnaire for persons with an intellectual disability
SOS: sum of social scores
the impact of APOE
61
the criteria, suspected of having dementia, after one assessment. This person passed away before 
the second assessment.
The SRZ scores show a strong correlation to the presence of the APOEε4 allele (see figure 2). After 
three assessment periods, following baseline, all the homozygotes (n = 7) for the ε4 allele met the 
screening criteria for dementia. We compared further the mean decrease in SRZ scores through 
the different assessments. Figure 3 shows that the decrease in mean scores increased overtime. 
Those homozygous for APOE ε4 had a significantly higher mean decrease than no carriers at the 
first and third assessment after baseline. The second assessment showed the same trend, though 
not statistically significant.
According to their level of premorbid intellectual disability, we divided our population in three 
different groups; mild, moderate and severe disabled. We used ANOVA, with Bonferroni correc-
tion for multiple testing, to detect, if there was a difference in the mean decrease in scores in SRZ 
and mean increase in scores in DMR after the first, second and third assessment period. We found 
no significant difference in mean decrease/increase between the three groups, according to their 
level of disability, after the different assessment periods. By interviewing the general practitioner 
we examine the possible use of drugs. None of our participants was using acetylcholinesterases or 
other pharmacological agents that may modify the SRZ or the DMR.
Figure 2 Decline according to the SRZ criteria over time, by APOEε4 genotype
Figure  2  
Decline according SRZ criteria over time by APOEε4 genotype 
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APoe and the risk of dementia
We determined the odds ratios of being demented or not at the baseline, by the APOE genotypes 
with the ε3/ε3 as reference (see table 2). There was an increase in the odds ratios in the presence of 
one or two APOEε4 alleles, but the odds ratio was not significant, OR:1.57, (95% CI = 0.87-2.82). 
There was no detectable association in our study population between APOEε2 and AD.
Figure 3 Mean decrease in SRZ scores over time by APOEε4 genotype
Figure 3 
Mean decrease in SRZ scores over time by APOEİ4 genotype 
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Table 2 Effect of the APOE genotype on the prevalence of dementia
Genotype demented nondemented¹ Odds Ratio² 95% Confidence 
Interval
ε2ε2 1 6 1.06 0.12-9.09
ε2ε3 10 49 1.29  0.59-2.81
ε2ε4 3 15 1.27 0.35-4.63
ε4ε3 18 70 1.63 0.86-3.08
ε4ε4 2 8 1.59 0.32-7.82
ε3ε3 33 210 reference
ε4 present
versus ε3ε3 
23 93 1.57  0.87-2.82
¹ numbers demented/non-dement at baseline
² odds ratio against the reference ε3ε3
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We also studied the risk of developing AD for persons with DS who were not demented at the 
baseline. After an average of 3.68 years of follow up, 53 persons were detected as new cases of de-
mentia (according to the criteria mentioned previously). For the initially non-demented APOEε4 
carriers, the risk of developing dementia, after a follow up time of at least 3 years, was significantly 
increased: HR: 4.66, (95%CI = 1.35-16.14) adjusted for age at entry, sex and level of intellectual 
disability. For those with a follow-up less than 3 years the risk was not significantly increased: HR: 
0.83, (95%CI = 0.35-1.94).
The effect of the APOEε4 allele on the age of onset was determined using the Cox Proportional 
Hazard model with age as the underlying time. There was no significant effect in our study popula-
tion of APOEε4 on the age at onset of AD: HR: 1.09, (95%CI = 0.56-2.12). Although the mean age 
of onset of AD among the APOE ε4 carriers was younger, 54.9 years (SD 3.6), compared to the 
non-carriers, 56.1 years (SD 5.5), this difference was not statistically significant.
Finally we added our data to the previous studies7, 9-11, 15-17, 32, 33, see table 3 and figure 4. This was 
only possible for the prevalent patients as all previous studies were based on prevalence. The meta-
analysis showed a statistically significant increase of the APOE ε4 allele in persons with DS and de-
mentia compared with those without dementia. The odds ratio of APOE ε4 was: OR: 1.59, (95% CI 
= 1.19-2.12) using a random effects model. Our meta-analysis did not show a significant decrease 
of the APOE ε2 allele frequencies in the demented persons compared with the non-demented 
persons. The odds ratio of APOE ε2 was: OR: 0.67, (95%CI = 0.37-1.22).
We divided the meta-analysis in a “ younger group” e.g. younger than 50 years: (Prasher22 , Lam-
bert32, Rubinstein17, Tyrrell15 and Sekijima33) and in an “older age group” (Coppus34, Lai16, van 
Gool7, Deb9, and Schupf11). The effect of APOE ε4 in the younger age group was not significant: 
OR: 1.49, (95%CI = 0.84-2.65). Only in the older age group was there a significant relation between 
the presence of an APOE ε4 allele and dementia (OR: 1.62, 95%CI = 1.15-2.29).
discussion
This is the largest study of APOE genotype and dementia in persons with DS that combines both 
cross-sectional and prospective data. When combining our cross-sectional data with those of 
other studies in a meta-analysis, we found APOEε4 was significantly associated to the prevalence 
of dementia in persons with DS, while our own prospective data showed an increase in incidence 
of dementia in APOE ε4 carriers when following participants more than 3 years.
We found no robust effect of APOE ε4 on mortality in our study, although the allele frequency 
of APOEε4 decreased significantly after the age of 60 years. Since dementia is the major cause 
of mortality in persons with DS aged 45 years and older, an effect of APOEε4 on dementia is in 
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line with the reduction of APOEε4 allele frequencies after the age of 60 years. A problem of the 
interpretation of the mortality data in the current phase of the study is that the analysis is based on 
only 60 deaths and therewith suffers from a low statistical power. It remains to be determined in 
the future whether APOEε4 predicts mortality after a longer follow-up.
There was significant evidence of an APOE ε4 effect on the rate of decline of social, and daily living 
skills in our study. In particular DS persons who were homozygous for APOEε4 showed a higher 
decrease in function when assessing decline using the SRZ, independent of their pre-morbid level 
of functioning. The SRZ appears to be a more sensitive screening instrument to pick up differ-
ences than the DMR. The latter instrument did not show this trend in cognitive function (DMR/
SCS), nor did it do so in the scores related to the social skills (DMR/SOS). Both instruments are 
informant-based questionnaires, which may be susceptible to recall bias. Although this could be 
a potential limitation for the DMR, this problem also concerns the SRZ. Since the SRZ appears to 
be useful in this study population this explanation seems less likely. Moreover, the errors in the 
questionnaire are expected to be independent of the APOE genotype of the person with DS.
For the initially non-demented APOEε4 carriers, the risk for developing dementia during the 
follow-up is not significantly related to APOE ε4 when considering a short follow up. The rela-
tive risk estimate as the hazard ratio of developing AD within 3 years after inclusion was: 0.83, 
(95%CI = 0.35-1.94). However in the long term the risk of AD was significantly increased: HR: 
4.66, (95%CI = 1.35-16.14). 
We found no significant evidence for an increased risk on the prevalence of dementia in our 
population. After pooling our prevalent patients with those of others, APOE ε4 was associated 
with a significant increased risk of AD in persons with DS: OR: 1.59, (95%CI = 1.19-2.12). When 
analysing our prevalent cases, the relative risk of 1.57, we found in our study, is extremely close to 
that we see in the meta analysis suggesting that the significant, 1.59-fold increase, in risk found, is 
the most reliable Bayesian estimate and that the absence of a significant association in our study 
may be due to power limitation.
Our study is the largest study of elderly persons with DS, who are examined clinically in person. 
The advantage of this single centre study is that we are able to screen our population for newly 
diagnosed patients annually. An important strength of the study is that all these patients were seen 
by the research physician making differences in diagnostic criteria across patients unlikely. We did 
not find an effect of APOEε4 on the age of onset of AD in our study population. This result may be 
influenced by the limited number of persons (53) who develop dementia during follow-up, which 
yields only a low statistical power. Schupf et al11 found that the APOEε4 allele was associated with 
an earlier onset of dementia using survival analysis of a series of 13 persons with DS who devel-
oped dementia. The age at onset of dementia was not affected by the APOE genotype in a survival 
analysis done in a study including 49 cases by Margallo-Lana et al21.
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The findings of our meta analysis, show evidence that APOE ε4 determined the prevalence of AD, 
in accordance with the results of Prasher et al10, but in contrast with the findings of Deb et al9. Us-
ing in the meta-analysis the same studies as Deb et al. did, supplied with our own study we found 
also evidence for an association: OR: 1.83, (95%CI = 1.23-2.72), suggesting that the findings of our 
meta-analysis and those of Prasher et al10 are statistically robust. When dividing the meta-analysis 
in a ‘younger’ and ‘older’ age group, the effect of APOE ε4 only remains significant in the older 
persons. 
In summary, our population based study and meta analyses show that the effect of APOE ε4, on 
the prevalence of dementia in persons with DS, is 1.6 times increased. After three years of follow-
up there also was a strong, fourfold, increase in risk of dementia. Although we could not have the 
power to show an effect on mortality, the reduction in APOE ε4 frequency in persons with DS after 
the age of 60 years suggest there is an effect. This increased mortality may explain the difference 
between the odds ratio in prevalent patients and the risk in newly diagnosed ones. Due to these 
findings we can suggest that APOE ε4 is important in Aβ aggregation in persons with DS.
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AbstrAct
The longer life expectancy now experienced by persons with Down’s syndrome (DS) makes it nec-
essary to know the factors influencing survival in older persons with this syndrome. In a prospec-
tive longitudinal cohort study of dementia and mortality, 506 persons with DS aged 45 and older 
were followed for a mean of 4.5 years (range 0.0-7.6 years). Cognitive and social functioning were 
tested at baseline and annual follow-up. The diagnosis of dementia was determined according to a 
standardized protocol. Cox proportional hazards modeling were used for survival analysis.
Relative preservation of cognitive and functional ability is associated with better survival in this 
study population. Clinically, the most important disorders in persons with DS that are related 
to mortality are dementia, mobility restrictions, visual impairment, and epilepsy but not cardio-
vascular diseases. Also level of intellectual disability and institutionalization are associated with 
mortality.
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introduction
In recent decades there has been a distinct trend toward longer survival in persons with Down’s 
syndrome (DS)1, increasing from 9 years in 1929 to 12 in 1949 and 49 years in 19972. In developed 
countries recent estimates indicate a mean age of death of older than 503-7. The change in mortality 
pattern raises the question of what the most important determinants of mortality are.
Despite major progress, persons with DS still show greater mortality rates early in life, as well as 
in later stages of life2, suggesting that there still may be differences from the general population. 
Knowledge of factors influencing survival in older persons with DS is limited. Nearly 20% of the 
persons with DS aged 45 years and older suffer from dementia8, and several studies have shown a 
greater risk of mortality for persons with DS and dementia or cognitive decline9-11. Cognitive de-
cline has been shown to be associated with mortality in elderly people with and without dementia 
with and without DS12, 13. In addition to age, other factors that have been suggested might influence 
mortality risk in DS are the gene encoding for apolipoprotein E (APOE)12, 14, 15 and co-morbidity3.
The objective of this study was to assess the effect of cognitive and functional decline and physical 
comorbidity on mortality risk over time in a population-based cohort of persons with DS aged 45 
and older. 
methods
study population
The design of this study, a prospective longitudinal study on dementia and mortality in persons 
with DS, has been described in detail elsewhere16. Briefly, 506 persons with DS, aged 45 years and 
older, were enrolled in the study from December 1, 1999 to December 1, 2003. All participants 
were monitored annually until they died (n = 109) or their representatives withdrew them from the 
study (n = 7), up to the reference date of January 1, 2007. At the time of study entry, each person 
received a complete assessment including interviews with relatives, caregivers, and their general 
practitioner. The medical records were reviewed to examine past or present disorders (e.g., cardio-
vascular risk factors, epilepsy and depression), mobility, and the possible use of drugs. All persons 
obtained a general physical and neurological examination and, if compliant, a venapuncture. The 
same questionnaires and interviews were used annually from 1999-2007.
Pre-morbid severity of intellectual disability, obtained from the medical records, was classified 
using the International Classification of Diseases, Tenth Revision (ICD-10)17. According to these 
criteria, 192 (38.5%) of the participants had a severe to profound level of intellectual disability, 
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and 250 (50.1%) had a moderate to mild level of intellectual disability. The severity of intellectual 
disability was not known for 57 (11.4%) participants.
The diagnosis of dementia was based on the ICD-10 Symptom Checklist for Mental Disorders, in 
particular, dementia and Alzheimer’s disease17, and according to the guidelines produced by an 
international consensus panel established under the auspices of the Ageing Special Interest Group 
of the International Association for the Scientific Study of Intellectual Disabilities (IASSID)18. Vital 
status was obtained using follow-up interviews and written correspondence. Information on causes 
of death was obtained from relatives or the primary caregivers of the deceased and was augmented 
with information from medical reports or autopsy records.
The medical ethical committee of the Erasmus Medical Center and the ethical committees of the 
local organizations approved the study protocol. Written informed consent to participate, and to 
provide blood samples, was obtained from legal representatives.
Written consent was also obtained from persons with DS who had the mental capacity to consent. 
diagnosis of dementia
Baseline
At baseline, the first line relative, the primary caregiver, and the general practitioner were asked 
to answer the question: “Has this patient been suffering from dementia for at least 6 months?” 
The research physician (A.M.W.C.) confirmed the diagnosis according to a standardized protocol, 
including a medical checklist and a physical examination. Participants fulfilling the criteria were 
included in the group of persons with dementia at the baseline, as prevalent cases.
Follow-up
Participants who did not have dementia at baseline were screened annually. Those who fulfilled 
the dementia criteria at baseline or during follow-up were followed more intensively at 6-month 
intervals. The diagnosis of dementia was supported using two observer-rated questionnaires, the 
Dementia Questionnaire for persons with an Intellectual Disability (DMR)19, 20 and the Social 
Competence Rating Scale for persons with an Intellectual Disability (SRZ)21. The DMR is a 50-
item questionnaire with two types of scores: those related to cognitive function (DMR/SCS; score 
range 0-44) and those related to social scores (DMR/SOS; score range 0-56). Higher DMR scores 
represent a higher frequency of behaviors that are considered to be indicative of dementia. The SRZ 
is a 31-item questionnaire (score range 0-124) and covers aspects such as social skills, daily living 
skills, and the effective use of language. Higher SRZ scores indicate better functioning. Diagnoses 
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of dementia were based on a clinical examination by the research physician (A.M.W.C.). Diagnostic 
examination was performed in patients who had a worsening of 7 points or more on the DMR/SCS 
scale, a worsening of 5 points or more on the DMR/SOS scale, or a 10% decrease of the SRZ score.
All new diagnoses were discussed in a panel consisting of members of the reference group with ex-
pertise in the field of intellectual disability (A.M.W.C., G-J.V, F.E.V and H.M.E.). A final diagnosis 
was based on consensus of the panel.
clinical assessments
The history of past or current disorders was ascertained using medical record review. Body Mass 
Index (BMI) was computed as weight in kilograms divided by height in square meters (kg/m2). 
Visual impairment was assessed using a picture-graded test (the Teller acuity card) and hearing 
ability using a simple speech and whisper test. Screening for mobility restrictions took place during 
the personal physical examinations, using a standardized protocol16. 
APoe
Blood samples for determination of APOE were collected from participants who provided consent 
(n=425). APOE genotypes were determined using the Taqman allelic discrimination technology. 
APOE genotyping was obtained blind to all clinical information and coded dichotomously for 
analysis. Participant had one or two APOEε4 alleles or no APOEε4 alleles. APOE allele frequencies 
were comparable with the general Dutch population15.
statistics
The risk of mortality according to participant characteristics and clinical diagnoses was investigated 
using Cox proportional hazards models, adjusting for age at baseline as a covariate. Follow-up time 
was defined according to date at entry and date at death or January 1, 2007. The risks of mortality 
between groups were compared by estimating hazard ratios in the Cox models. Survival analyses 
were performed in persons for whom complete data were available (75.8%).
The relationship between rate of decline in DMR and SRZ and risk of mortality was investigated 
in persons without dementia using a mixed-model repeated-measures procedure22. This procedure 
takes into account that the same individual contributes information at different time points and 
allows the inclusion of persons with incomplete follow-up. Decline in functioning was investigated 
in patients with at least 5 years of follow-up (n = 483), totaling five measurements of cognitive, 
functional and social ability. Participants were categorized into three groups, according to their 
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DMR and SRZ scores at baseline. Mean DMR and SRZ scores were compared between tertiles and 
between survivors and decedents. 
To further investigate the effect of age and birth cohort effects, the study population was divided 
into two birth cohorts based on the participant’s age at the reference date. The birth cohorts dis-
tinguished patients who were aged 60 and older (born before 1947; n = 118) and those who were 
younger than 60 (born after 1947; n = 381). There were more persons with a profound or severe 
intellectual disability in those born before 1947 (31.3% versus 17.6%, p = 0.01). The cohorts did not 
differ according to sex or living situation. Follow-up time was defined according to date at entry 
into the study and date at death or January 1, 2007 as exit. 
To establish whether there was a relationship between the presence of an APOEε4 allele and sur-
vival, the Cox models were additionally adjusted for sex, pre-morbid severity of intellectual disabil-
ity, and living situation. To investigate whether the relationship between APOEε4 and survival was 
related to dementia status or birth cohort, the Cox analyses were repeated in subgroups stratified 
according to dementia status and in subgroups stratified according to birth cohort. In persons 
without dementia, the time to event variable was time since entry into the study, until incidence 
of dementia, until death or the reference date. Also in persons with dementia, the time to event 
variable was time since entry into the study, although in the incident persons with dementia, it was 
the time since onset of dementia until death or the reference date. 
Finally, the Cox analysis was repeated including all covariates found to be related to mortality risk. 
To exclude that inclusion of patients in the final stages of dementia explained the relationship be-
tween poorer mobility and mortality, the analysis was repeated without persons known to be in the 
terminal phase of dementia23.
results
A total of 506 persons with DS were studied, of whom 304 were men (60.1%). At baseline the mean 
age was 51.9 for men (range 45-70) and 52.0 for women (range 45-77). Seven persons, or their 
relatives, refused to participate in the study during the follow-up time, leaving 499 participants. 
The mean follow-up time is 4.5 years (range 0.0-7.6 years). At January 1, 2007, 78.2% of the original 
study population was alive. One hundred nine persons had died, yielding a mortality rate of 4.8 per 
100 person years. 
There was no significant difference between men and women in mean age at death (57.7 versus 58.4 
years; p = 0.61), and there was no significant sex difference in survival (Chi-square = 0.11; p = 0.73). 
Mean age at death for persons without dementia (n = 29) was 56.6 and did not differ significantly 
(p = 0.12) from that of persons with dementia (58.5, n = 80). 
survival in Down’s syndrome
77
Patients died of respiratory disease (n = 38), cardiac failure (n = 8), cerebrovascular disease (n = 9), 
carcinoma (n = 7), epilepsy (n = 2) and other diseases (frequency n = 1). The frequencies of causes 
of death were significantly different between persons with DS with and without dementia (p < 
0.01). Physical health conditions and special respiratory problems were most frequently a cause of 
death in persons with dementia, and cardiac failure was the most frequent cause of death in persons 
without dementia. Cause of death was not known in one-third of those who had died.
The risk of mortality according to patient characteristics and different health conditions are de-
scribed in Tables 1 and 2. Older persons at baseline, those with physical handicaps, those living in 
institutions, and those with a severe to profound level of intellectual disability were more likely to 
have died during follow-up (Table 1). Mortality risk was significantly related to morbidity (Table 2), 
except for depression and cardiovascular conditions and risk factors. The presence of a cardiovas-
cular condition or risk factor was not associated with greater mortality risk. 
A decrease in function over the annual assessment periods was observed in the DMR and SRZ 
scores in patients without dementia (figure1). Participants who had died after 5 years of follow-
up showed significantly greater decline in functioning, than those who survived at all levels of 
performance (p < 0.001).
Table 1 Vital Status at Follow-up and Risk of Mortality According to Baseline Characteristics
Characteristics Survivors Decedents HR (95%CI) p-value
All, n (%) 390 (78.2) 109 (21.8)
Sex, n (%)
  Women 154 (39.5) 45 (41.3)
  Men 236 (60.5) 64 (58.7) 1.10 (0.75-1.63)†  0.62
Age start, years, mean (SD) 51.0 (4.5) 55.4 (6.2) 1.15 (1.12-1.19)  <0.001
Birth cohort
  Born before 1947 64 (16.4) 54 (49.5)
  Born after 1947 326 (83.6) 55 (50.5) 0.24 (0.16-0.35)  <0.001
Level of ID, n (%)
  Moderate  to mild 209 (60.6) 41 (42.3)
  Severe to profound 136 (39.4) 56 (57.7) 1.84 (1.22-2.77)†  0.003
Living situation, n (%)
  Community living 154 (39.5) 29 (26.6)
  Institutionalised 236 (60.5) 80 (73.4) 1.67 (1.08-2.57)†  0.02
APOEε4 allele, n (%)
  Absent 254 (74.3) 55 (66.3)
  Present   88 (25.7) 28 (33.7) 1.58 (1.00-2.50) †  0.05
HR = Hazard Rate
CI = Confidence Interval 
ID = Intellectual Disability
SD= Standard Deviation
†  = Adjusting for age
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In persons with DS younger than 60, persons with dementia had a 6 times greater mortality risk 
than those without (Hazard rate (HR): 6.11, 95% confidence interval (CI) = 3.34-11.17). In persons 
aged 60 and older, the risk was 2.79 times as great (95%CI = 1.49-5.26), although the difference in 
HR between the two birth cohorts was not statistically significant (p = 0.46).
A significant 1.64 times greater risk of mortality (95%CI = 1.01-2.64; p = 0.04) was found for 
APOEε4 carriers. The presence of at least one APOEε4 allele was associated with greater mortality 
risk in persons with and without dementia, but these associations were not statistically significant 
(HR: 1.07, 95%CI = 0.58-1.95, and HR: 1.64, 95%CI = 0.88-3.01, respectively).
The association between APOEε4 and survival did not differ between the two birth cohorts.
Finally, age at baseline, severity of intellectual disability, living situation, dementia status, epilepsy, 
mobility, visual impairment and APOEε4 carrier status were studied in a multivariate survival 
analysis. Only dementia (HR: 4.03, 95%CI = 2.16-7.49; p <0.001), age at baseline (HR: 1.11, 95%CI 
= 1.05-1.16; p <0.001) and a restricted mobility (HR: 1.92, 95%CI = 1.06-3.46; p = 0.03) remained 
significantly associated with mortality risk. Excluding patients in the terminal phase of dementia 
did not alter the results.
discussion
Age, presence of dementia and mobility restrictions are the most important predictors of mortality 
in this study cohort of almost 500 people with DS aged 45 and older. In contrast to the general 
population, impaired mobility, severity of intellectual disability, the presence of epilepsy and visual 
Table 2 Vital Status at Follow-up and Risk of Mortality According to Morbidity at Baseline
Characteristic
Survivors        Decedents n(%) HR (95%CI) p-value
Epilepsy 69 (20.6) 40 (44.4) 2.29 (1.50-3.48)  < 0.001
Depression 84 (25.7) 32 (36.8) 1.41 (0.91-2.19)  0.12
Prevalence of dementia at baseline 45 (11.5) 40 (44.4) 2.91 (1.94-4.36)  < 0.001
Incidence of dementia during follow-up 57 (14.6) 38 (34.9) 1.97 (1.32-2.94)  < 0.001
Vision < 30% at baseline 135 (37.3) 62 (63.9) 2.33 (1.54-3.55)  < 0.001
Hearing impairment at baseline 136 (46.5) 45 (61.6) 1.55 (0.94-2.56)  0.08
Mobility restriction n (%) 72 (19.5) 55 (51.9) 2.76 (1.85-4.13)  <0 .001
Cardiovascular risk factors, n (%)† 77 (19.7) 20 (18.5) 0.96 (0.59-1.57)  0 .88
HR = Hazard Rate
CI = Confidence Interval
SD = Standard Deviation
 † Cardiovascular conditions and risk factors were rare. Therefore, we combined diabetes mellitus (n = 6), hypertension (n = 
8), cerebrovascular disease (n = 12), known myocardial infarction (n = 2), and smoking (n = 72). 97 Participants had more 
than one condition/risk factor.
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impairment, not cardiovascular risk factors or sex, predicted survival. From a population perspec-
tive, one of the most remarkable findings was that sex did not predict mortality. It is most likely 
that the fact that mortality from cardiovascular disease is not an important cause of death in this 
population (neither in absolute numbers nor as predictors of mortality) explain this.
Before interpreting the results of this study, three methodological issues need to be addressed. 
First, the study focused on elderly persons with DS and included persons aged 45 and older. No 
Figure 1 Mean Scores of functioning in Persons without Dementia after 5 years of Follow-up
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information was available on persons who died before the age of 45. This means that several of 
the findings remain unexplained, such as the lower percentage of women in the study population. 
Second, some of the data were collected retrospectively from the medical records, which implies 
that the accuracy of the assessments such as premorbid level of intellectual disability could not be 
controlled, yet these assessments are relatively standard or part of usual care. Third, DMR and SRZ 
were informant-based questionnaires, completed by caregivers. Participants may have had differ-
ent caregivers during follow-up, and their living situation may have changed. Reference standards 
may have differed and affected the observed performance of the participant, observation bias can-
not be excluded. Nevertheless, all participants were followed longitudinally for clinical signs of 
dementia. A final diagnosis of dementia was based on consensus of a panel consisting of members 
of the reference group.
A gradual decrease in function in the participants without dementia in this study was documented 
(see figure1). Although they never met the criteria of dementia, these persons showed a decline in 
cognitive and functional skills during follow-up. More extensive longitudinal studies are required 
to identify whether it was likely that this decline was the result of the preclinical onset of AD or of 
normal aging in DS. One of the clinical challenges will be to discriminate between persons with 
faster and slower decline. 
Even in participants not suffering from clinically manifest dementia, more rapid decline was as-
sociated with a greater risk of mortality. This finding is in line with those of others, in subjects 
with and without DS12, 13, 24, 25, although the current study is the largest in persons with DS, with 
all participants examined in person and a clinical follow-up. The results of this study, using dif-
ferent screening instruments, show a decline, in participants without dementia, irrespective of the 
previous level of performance. Although, it is difficult to detect a decline in those with the lowest 
level of performance, this decline, monitored by screenings tests, was related to mortality even in 
this group. In addition, other studies7, 26-28 have shown a significant negative association between 
severity of intellectual disability and survival, although this relationship did not remain significant 
in the multivariate analyses, including all predictors.
This study found an effect of the APOEε4 allele on mortality. Persons with one or two APOEε4 
alleles have a 1.64 times greater mortality risk (95%CI = 1.01-2.64). However, this greater risk did 
not remain significant after adjusting for dementia, although in persons with dementia and in 
particular in persons with DS without dementia, the risk remained greater (HR: 1.64, 95%CI = 
0.88-3.01). This estimate is lower than found in a previous study14, which found that persons with 
at least one APOEε4 allele were approximately 5 times as likely to die (4 out of 27 APOEε4 carri-
ers) in a 5- to 7 years follow-up study of persons with DS without dementia. In addition cognitive 
decline in persons without dementia is a predictor of mortality. Taken together with the findings 
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of APOEε4, these findings suggest that early pathology that does not express clinically as dementia 
is associated with mortality in persons with DS.
Because of the longer life expectancy, and their living in the community, persons with DS come 
to the attention of general practitioners and clinicians specializing in the care of elderly people. 
An important clinical implication of the data presented in this study is that these clinicians should 
focus not on cardiovascular risk factors but on impaired mobility and respiratory complications. 
Diseases of the respiratory system seem to be the most important cause of death in persons with 
DS with dementia. 
In one-third of those who died, the cause of death could not be determined. This finding indicates 
the need for further clinical and pathological research. The limitation will be whether clinicians 
are willing to ask for autopsies. 
Age and dementia have long been recognized as major predictors of mortality. This study dem-
onstrates that other factors, such as underlying and associated disorders, mobility, morbidity, and 
social and functional skills also contribute to survival.
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AbstrAct
In a prospective longitudinal cohort study of dementia and mortality in persons with Down’s 
syndrome (DS) aged 45 years and older, 85 postmenopausal women were followed for a mean 
follow-up time of 4.3 years (range 0.0-7.4 years). The effect of age at menopause on age at diagnosis 
of dementia and survival was estimated using correlation analysis and the Cox Proportional Haz-
ard Model. We found a significant correlation between age at menopause and age at diagnosis of 
dementia (ρ = 0.52; p< 0.001), and between age at menopause and age at death (ρ = 0.49; p = 0.01). 
Early age at menopause, before 45 years, is associated with a 1.8 fold increased risk of dementia: 
Hazard Ratio (HR): 1.82 (95% Confidence Interval (CI) = 1.31-2.52) and with risk of death: HR: 
2.05 (95%CI = 1.33-3.16). Our study suggests that age at menopause in women with DS is a deter-
minant of age at onset of dementia and mortality. 
age at menopause
87
introduction
Whereas the general population shows a clear excess of women in the elderly, the population of 
elderly Down’s syndrome (DS) patients is characterized by an excess of men, which is seen consis-
tently across populations1-4. The origin of the excess males in elderly patients with DS is not clear. 
A small excess of males is seen at birth but this cannot explain the 3:2 ration of men to women 
in the elderly5-7. There also may be excess mortality early in life in females due to the increased 
prevalence of congenital heart diseases and auto-immune disorders in women1,3. However, this is 
not likely since most of these conditions are not lethal with the current standard of treatment. We 
have shown that the presence of dementia is one of the most important predictors of mortality in 
a study cohort of 506 persons with DS aged 45 years and older7. Although data are scarce, women 
with DS appear to have an earlier age at menopause than women in the general population8-11.
We hypothesised that the earlier menopause, including the reduction in estrogens following 
menopause, contributes to the earlier onset and increased risk of Alzheimer’s Disease (AD) in 
women with DS12. At present, there are no data on how age at menopause relates to age at mortality 
in women with DS.
We tested the hypothesis that an earlier age at menopause is associated with the age at onset as well 
as the risk of AD and mortality in elderly women with DS.
methods
study population
Our study included 199 women with DS who were enrolled from December 1, 1999, to December 
1, 2003 in a population-based study on DS and ageing in the Netherlands. The sampling proce-
dures and inclusion criteria for this study have been described in detail elsewhere7. At the time of 
study entry, each person received a complete assessment of cognitive, functional and health status, 
including interviews with relatives, carers and their general practitioner. All participants obtained 
a general physical and neurological examination and if compliant a venapuncture. Participants 
that were not demented at baseline were screened annually, until they died, or up to the reference 
date of January 1, 2007. Those who fulfilled the dementia criteria, at baseline or during follow-up, 
were followed more intensively at 6-month intervals. These patients also received a clinical work-
up, to exclude other physical and psychiatric factors as the possible cause of decline. Plasma and 
serum were stored at -80°C and DNA was isolated. The medical ethical committee of the Erasmus 
Medical Center and the ethical committees of the local organizations approved the study protocol. 
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Written informed consent to participate and to provide blood samples was obtained from legal 
representatives.
diagnosis of dementia
Diagnosis of Alzheimer’s disease was assessed using the International Classification of Diseases, 
Tenth Revision (ICD-10)13 criteria and according to the guidelines produced by the Ageing Special 
Interest Group of the International Association for the Scientific Study of Intellectual Disabilities 
(IASSID)14. 
For the prevalent cases of dementia, age at entry was used to estimate the age at diagnosis of 
dementia. Age at diagnosis of patients with incident dementia was determined as the midpoint 
between the age of the person last known to be at risk for dementia and age at diagnosis. All new 
diagnoses were discussed in a panel consisting of members of the reference group with expertise 
in the field of intellectual disability (A.M.W.C., G-J.V., F.E.V. and H.M.E.). 
clinical assessments
Pre-morbid severity of intellectual disability (ID) was classified into two groups, using the Inter-
national Classification of Diseases13: mild/moderate (IQ 35-70) and severe/profound (IQ <35). 
APOE genotype was determined as described in a previous study15. Participants were classified 
according to the presence or absence of at least one APOEε4 allele. The history of past or current 
hypothyroidism was ascertained by reviewing the medical records. The Body Mass Index (BMI) 
was computed as weight in kilograms divided by height in square meters (kg/m2).
Age at menopause was ascertained by medical record review and interviews with carers and fam-
ily members. Menopause was defined as cessation of menses for at least 12 months and age at 
menopause as the age of the last menstruation. A total of 11 women were pre-menopausal at 
baseline and at follow-up and for 33 the menopausal status was unknown. Of the 33 women with 
unknown status, 14 women still were using oral contraceptives and 6 women had a hysterectomy 
while for 13 there was no information available at all. Of the 155 women who were definitely post-
or-perimenopausal at baseline or follow-up, for 85 (55%) women the exact age at menopause was 
known. All women had a natural menopause, except one who had an oophorectomy at the age 
of 38 years. None of the postmenopausal women was on Hormone Replacement Therapy during 
the analyses or before study entry. For each participant, we obtained the vital status by follow-up 
interviews and written correspondence. 
age at menopause
89
statistical Analysis
To study the association between age at menopause and age at diagnosis of dementia, we used 
Pearson (ρ) correlation analysis. The median age of menopause (45 years) was used as cut-off 
point, to compare the groups, with an earlier age at menopause (before 45 years) to those with a 
later onset of menopause (after 45 years). The risk to develop dementia during follow-up by age at 
menopause was investigated using Cox proportional hazards models.
Entry time was defined as age at menopause. Censoring age was defined as age at diagnosis of de-
mentia, age at death or age at the end of this study, January 1, 2007, whichever came first. Potential 
confounders, influencing the age at menopause, as level of intellectual disability, Body Mass Index 
(BMI), a history of past or current hypothyroidism and the presence of an APOEε4 allele were 
studied using correlation analysis.
We repeated all analysis to study the association between age at menopause and mortality. In the 
Cox proportional hazards model, entry time was defined, as age at menopause, censoring time was 
age at death or January 1, 2007.
results
Characteristics are shown in Table 1. The postmenopausal women with information of menopause 
(n = 85) did not differ significantly from those without information (n = 70). At the baseline the 
mean age of these 85 women was 51.7 years (range 45-67). The mean length of follow-up was 4.3 
years (range 0.0-7.4 years). At January 1, 2007, 63 women (74%) of the original study population 
were alive. The mean age at menopause was 44.0 years (minimum 28-maximum 55 years); the 
median age was 45 years. Of these 85 women for whom age at menopause could be determined, 
37 were demented (incident and prevalent), of whom 19 women died during follow-up (51.4%). 
We found no significant correlation between age at menopause and the presence of an APOEε4 
allele (p = 0.89); level of intellectual disability (p = 0.69); BMI (p = 0.85) and the presence of 
hypothyroidism (p = 0.06).
Figure 1a shows that there is a strong and significant correlation between age at menopause and 
age at diagnosis of dementia (Pearson ρ = 0.52; p = 0.001). In line with these findings, women 
with an early onset of menopause (before45 years) had an earlier onset of dementia compared 
with women with a later (after 45 years) onset of menopause [52.5 years (SD3.5) versus 59.3 years 
(SD 7.2) respectively (p = 0.02)]. The Cox proportional Hazard model showed that the early age 
at menopause was significantly associated to the risk of dementia. Per 5 years interval, the hazard 
ratio (HR) was 1.82 fold (95%CI = 1.31-2.52) increased for those with an early menopause.
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Table 1 General Characteristics of the study population
Postmenopausal women 
Information available age at menopause
Premenopausal 
women
Unknown status
menopause
yes no p-value
No. of participants    85 70 11 33
Age at entry 51.7 (4.8) 52.9 (5.8) 0.14 48.8 (3.9) 52.1 (6.2)
Intellectual Disability
Severe to profound 
Mild to moderate 
19 (25)
56 (75)
21 (37)
36 (63)
0.27
0.07
1 (12.5)
7 (87.5)
13 (44.8)
16 (55.2)
APOEε4 positive 16 (22.9) 10 (18.5) 0.56 3 (30) 4 (16.7)
Body Mass Index 27.3 (4.6) 27.2 (4.6) 0.72 27.9 (6.7) 27.5 (4.7)
Age at menopause
Menopause before 45 years
44.0 (4.7)
58 (68.2)
Dementia status
Prevalent demented
Age at diagnosis prevalent cases
Incident demented
Age at diagnosis incident cases 
21 (25)
53.1 (4.2)
16 (19)
55.1 (6.0)
11 (16)
55.3 (8.9)
17 (24)
55.4 (4.4)
0.17
0.30
0.40
0.86
0
/
3 (27.3)
53.7 (5.8)
4 (12.1)
49.8 (2.7)
4 (12.1)
57.5 (5.6)
Mortality *
Age at death*
22 (25.8)
57.9 (6.5)
17 (24.3)
58.9 (6.5)
0.82
0.43
0
/
6 (18.2)
60.1 (8.3)
Data were reported as mean ± standard deviation (SD) or number and percentage
P-values: we used chi-square tests for categorical variables and Student’s t-test and analysis of variance for continuous variables 
to compare the postmenopausal women with and without information about age at menopause.
For definitions see methods
* At reference date:  January,1, 2007
Figure 1a Age at onset of menopause and age at diagnosis of dementia, in women with Down’s syndrome
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Age at diagnosis of dementia: see methods
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To answer the question whether there is an association between age at menopause and mortality, 
we demonstrate in figure 1b that there also is a strong and significant correlation between age at 
menopause and age at death (Pearson ρ = 0.49; p = 0.01). The mortality of women with an earlier 
menopause is significantly earlier than that of the women with a later onset [54.8 years (SD5.6) ver-
sus 60.1 years (SD 5.0) (p = 0.03)]. Also, in a Cox proportional Hazard model, age at menopause was 
significantly associated with a greater risk of death, the HR being 2.05, (95%CI = 2.05 (1.33-3.16).
discussion
In this prospective study cohort of 85 postmenopausal women, we found that the mean age of 
menopause is relatively early (mean 44 years) compared to that seen in the general population 
(mean 51.4 years)16. We further found that age at menopause is significantly correlated with age at 
dementia diagnosis and age at death. Finally, our study showed that an early age at menopause is 
associated with an increased dementia ánd higher mortality risk.
In line with others10, we demonstrated a correlation between age at menopause and age at de-
mentia onset. Data of menopause in women with DS are very scarce and of low quality. However, 
the earlier menopause of women with Down syndrome has been recognized for long in clinical 
series. The origin of the early menopause in women with Down syndrome is not known but is not 
Figure 1b Age at onset of menopause and age at death in women with Down’s syndrome
Figure 1 b 
Age at onset of menopause and age at death in women with Down syndrome 
 
 
age at menopause
60504030
A
ge
 a
t d
ea
th
80
70
60
50
40
Age at onset of menopause and age at death in women with Down’s syndrome:
Number of persons who died during follow-up: n=22
Chapter 2.4
92
unexpected as all patients show accelerated ageing of various organs including the brain and skin17-
19. The early menopause may be related to either the aging of the brain, sex organs, or unrecognized 
genes over-expressed in the patients due to trisomy 21. Only one other group has studied the rela-
tionship with dementia8, 10-12, 20, 21. As the amyloid deposition, which is the origin of the dementia in 
DS patients, starts already in the second decade of patients with DS, it is unlikely that menopause 
or the withdrawal of estrogen itself after the menopause, initiates the deposition of beta-amyloid. 
More likely, menopause modifies the risk of dementia.
In our study, we also found a strong association of age at menopause and mortality. This is the 
first study in which a relation between age at menopause and mortality in women with DS is 
described. Age at menopause is strongly and significantly correlated to age at death (ρ = 0.49, 
p=0.01). Further, there is a two-fold increase in risk of mortality in women after menopause, which 
may contribute to the excess of men seen in elderly patients with Down syndrome. Unfortunately 
we do not have enough statistical power in this population, to study, in a multivariate analysis, the 
risk to develop dementia and the risk to die, adjusting for variables known to influence dementia 
and mortality. Age at menopause was not significantly correlated to the presence of an APOEε4 
allele, level of intellectual disability, BMI and the presence of hypothyroidism, suggesting these 
factors are not likely confounders.
The strength of this study is its prospective design, allowing a very careful evaluation of the age of 
menopause. Many women with DS in the Netherlands are on oral contraceptives, making it dif-
ficult to determine age at natural menopause. We could determine the exact age of natural meno-
pause in 55% of the women. Another potential problem is that selection bias could have occurred 
prior to study entry. Women with a very early menopause and women with an APOEε4 allele may 
have a higher risk to die before entry in the study. As a result, women with an early menopause that 
carry an APOEε4 allele who survived and entered the cohort may have been healthier than women 
with a later menopause and thus at lower risk of dementia. Similar to other studies, it is difficult for 
many women to pinpoint the age at menopause. 
In sum, our study shows that women with Down syndrome have an earlier menopause. This most 
likely reflects the accelerated ageing process, either in the brain, sex organs or may be related 
to unrecognized genes overexpressed in the patients due to trisomy. More importantly from a 
clinical perspective, age at menopause is strongly correlated to age at dementia and age at death. 
Further age at menopause is a determinant of the risk of dementia and mortality. It remains to be 
determined what the mechanism is underlying the association. However, an important clinical 
implication of our findings is that women with DS may be screened for dementia more intensively 
after menopause. Finally, the association may explain the excess of men among elder DS patients.
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AbstrAct
In persons with Down’s syndrome (DS) immunological abnormalities as well as hypothyroidism 
and Alzheimer type dementia are frequently observed. In addition, the activity of the enzyme 
cystathionine beta-synthase (CBS) is over-expressed which results in an altered homocysteine 
metabolism.
In the present study, 48 older healthy DS persons without signs of dementia, psychiatric or somatic 
comorbidity and free of medication were analysed for plasma levels of amino acids, neopterin and 
monoaminergic metabolites. Data were compared with those obtained from age and sex matched 
healthy controls. 
It was found that the spectrum of amino acids showed widespread differences in that levels of 
nearly all essential amino acids were lower in DS patients as compared to healthy controls. In 
addition, a significantly lower methionine and higher taurine concentration were observed which 
is in accordance with a disturbed homocysteine metabolism. With respect to the monoamine 
metabolites, the concentration of 5-hydroxyindoleacetic acid was not altered whereas that of ho-
movanillic acid was significantly increased. Finally, the concentration of the immune activation 
marker neopterin was increased in persons with DS.
It is concluded that healthy DS persons of older age show extensive biochemical abnormalities sug-
gesting a compromised homocysteine metabolism, an activated cell-mediated immune response 
and an enhanced turnover of dopamine.
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introduction
Down’s syndrome (DS) or trisomy 21 is the most common form of intellectual disability with 
an overall prevalence of 1,42/1000 that increases significantly with maternal age1. Immunological 
abnormalities like functional impairments in fagocytes with low chemotactic ability as well as 
the depressed production of cytokines are intrinsic to the chromosomal disorder and result in an 
increased morbidity and mortality from infectious diseases2. In addition, DS is associated with 
hypothyroidism in 20-40% of the patients and with neuropsychiatric disorders of which depres-
sion and Alzheimer-type dementia are the most frequent3-5.
Since the activity of the enzyme cystathionine ß-synthase (CBS), which is encoded on chromo-
some 21 (21q22.3), is associated with the level of intelligence and with neuropsychiatric disorders6, 
7, the concentration of CBS was recently investigated in post-mortem brains of DS persons8. It 
was found that the concentration of CBS was three times higher as compared to brain levels of 
normal individuals. CBS catalyzes the conversion of homocysteine and serine into cystathionine. 
The latter dipeptide is further metabolized into the amino acids cysteine and eventually to taurine. 
In humans, the sole source of homocysteine is through dietary intake of the essential amino acid 
methionine9, 10.
Thus, the over-expression of CBS in persons with DS may alter homocysteine metabolism result-
ing in a metabolic imbalance such that folate-dependent resynthesis of methionine is compro-
mised, and may be in favour of the transsulfuration pathway, leading eventually to increased levels 
of taurine11. Due to the dosage effect of CBS, a decrease in plasma concentration of serine was 
found in DS persons. In addition, an increase in plasma lysine, which was explained by generalized 
premature aging in DS, was observed12. 
Another amino acid abnormality is a decrease of systemic glutamate uptake as assessed by mea-
suring glutamate uptake in platelets and fibroblasts from DS persons13. The authors suggest the 
use of this peripheral model as a biochemical ex vivo marker of a central glutamatergic dysfunc-
tion. Excessive glutamatergic stimulation as a consequence of glutamate uptake deficits could 
be responsible for neuronal suffering, excitoxicity and cell death, and may play a key role in the 
pathophysiology of neuropsychiatric disorders14. 
Apart from the abovementioned amino acid abnormalities, impaired immunological function 
in DS persons results in increased serum neopterin levels15. Neopterin is not only an immune 
activator for the cell-mediated immune response, but also induces or enhances cytotoxicity and 
exhibits antioxidant properties16. This observation is consistent with the increased susceptibility of 
DS persons to bacterial and viral infections17.
No studies have been reported on the measurement of peripheral precursors or metabolites of the 
neurotransmitters serotonin and dopamine in DS. Since serotonin is involved in brain growth and 
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maturation, and experimentally induced high dopamine turnover may give rise to toxic metabo-
lites and neurodegeneration18-20, measurement of peripheral correlates of central serotonin and 
dopamine metabolism is also warranted. Since at least 40% of circulating homovanillic acid (HVA) 
originates from the brain, the plasma HVA concentration is thought to be a fairly good indicator 
of the changes in dopamine metabolism in the brain21. In addition, plasma 5-hydroxyindoleacetic 
acid (5-HIAA) is suggested to be an indicator of brain serotonergic activity22.
The present study was designed to investigate peripheral parameters that reflect changes in homo-
cysteine metabolism, immune function and monoaminergic neurotransmission in a group older 
non-demented healthy persons with DS. To this end, especially the sulphur containing amino 
acids methionine and taurine as well as serine, glycine, glutamate, lysine, tryptophan and the other 
large neutral amino acids (LNAA) were measured. The ratio of tryptophan to LNAA is a fairly 
good indicator of central serotonin synthesis. Concentrations of the dopamine and serotonin me-
tabolites HVA and 5-HIAA were determined as well as the levels of the immune activation marker 
neopterin.
mAteriAls And methods
subjects
Over a period of 4 years a community based sample of 506 DS persons aged 45 year and older from 
the Southern and the Southwestern parts of the Netherlands was collected. The study protocol 
was approved by the Medical Ethical Committee of the Erasmus University Medical Centre in 
Rotterdam, The Netherlands (protocol number: MEC 185.974/1999/202). In addition, the ethical 
committee of the local institutions provided approval. Written informed consent was obtained 
from the legal representatives. Details of the study population and the used screening instruments 
are presented elsewhere23. 
For the present study persons were excluded in case of any relevant somatic comorbidity, includ-
ing hypothyroidism and epilepsy, or the presence of a depressive disorder and signs of dementia. 
All persons were free of medication, including the use of folic acid, and did not smoke. The study 
group comprised 48 persons with DS (female: 11; male: 37; mean age: 50, Standard Deviation (SD) 
4.8 years) of whom 2 had to be excluded because of laboratory problems, and was compared to 
a group of 48 age and sex matched healthy controls (female: 16; male: 32; mean age: 50.2, SD 9.1 
years). 
plasma amino acids and neopterin
101
biochemical analyses
Plasma amino acids are analyzed by high-performance liquid chromatography (HPLC) using pre-
column derivatization with o-phthaldialdehyde24. The tryptophan-ratio (Trp-ratio) is calculated 
by dividing the total tryptophan level by the sum of the other large neutral amino acids (LNAA), 
i.e. valine, isoleucine, leucine, tyrosine and phenylalanine, which compete for the transport of 
tryptophan through the blood-brain barrier. The tyrosine-ratio (Tyr-ratio) is calculated in the 
same manner by substituting tryptophan for tyrosine. The concentrations of the monoamine me-
tabolites 5-HIAA and HVA are analyzed by HPLC and electrochemical detection25. The concentra-
tion of neopterin in plasma is determined as previously described26.
statistical analyses
For statistical comparisons between persons with DS and controls, the unpaired T-test was used 
because all data sets showed a normal distribution. Normality of the distribution was tested with 
the Kolmogorov Smirnov test. A value of p <0.05 was considered to be statistically significant. In 
case of finding statistically significant values for biochemical parameters, discriminant analysis 
was performed in order to assess the potential for further differentiating DS persons from controls, 
and to establish their relative contribution to the group difference.
results
As can be inferred from Table 1, the concentrations of methionine, glutamate and all LNAA are 
significantly decreased in the DS group as compared to the control group. Of the LNAA, trypto-
phan shows the lowest significance. The concentrations of taurine and glycine are significantly 
increased in DS persons as compared to controls, whereas the level of glutamate is significantly 
decreased. In addition, the Trp-ratio but not the Tyr-ratio, is significantly higher in the DS group 
compared to the controls.
With respect to neopterin, values in the DS group are significantly increased as compared to the 
control group. Furthermore, plasma HVA levels are significantly higher in the DS group, whereas 
no differences are found regarding 5-HIAA concentrations.
Finally, discriminant analysis (stepwise method) of the biochemical parameters with p-values 
<0.001 (valine, isoleucine, leucine, methionine, taurine and Trp-ratio) results in a discriminant 
function with valine, methionine and taurine as major predictors. Classification results are good: 
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84.8% of the DS persons were correctly classified, as were 83.3% of the controls. As a whole 16% 
was wrongly classified.
discussion
In the present study biochemical parameters related to neurotransmission and immunological 
function were investigated in a group of older persons with Down syndrome. It was found that the 
spectrum of amino acids shows widespread differences in the DS group as compared to controls. 
More specific, the amino acids valine, methionine and taurine were demonstrated to differentiate 
persons with DS from controls. Nearly all values of amino acids are lower in the DS group, which 
cannot be explained from dietary effects since all persons were provided with well-balanced meals. 
Besides, Ciaccio et al.27 reported that dietary measures over one year have an only marginal influ-
ence on the plasma concentration of amino acids in children with DS. 
With respect to the CBS-related parameters, plasma methionine was found to be significantly 
lower, while taurine was higher. In addition, plasma serine was slightly decreased in DS persons. 
These observations are in accordance with an over-expression of the CBS-gene in DS28-30 and 
are also in line with results concerning serine and taurine plasma concentrations as reported by 
Table 1 Plasma levels (mean ± S.D.) of biochemical parameters in persons with Down’s syndrome and 
controls
Biochemical parameter DS patients Healthy Controls p-value
Tryptophan (µmol/l) 47.1 ± 6.1 (46) 50.4 ± 9.0 (48)   0.040
Tyrosine (µmol/l) 61.9 ± 12.6 (46) 71.0 ± 17.3 (48)   0.004
Valine (µmol/l) 226.5 ± 42.8 (46) 286.2 ± 59.7 (48)   0.000
Phenylalanine (µmol/l) 58.0 ± 8.5 (46) 63.1 ± 10.0 (48)   0.010
Isoleucine (µmol/l) 61.2 ± 11.7 (46) 82.7 ± 24.1 (48) <0.000
Leucine (µmol/l) 122.6 ± 20.9 (46) 148.5 ± 31.8 (48) <0.000
Methionine (µmol/l) 25.6 ± 4.7 (46) 32.0 ± 6.5 (48) <0.000
Taurine (µmol/l) 53.9 ± 11.8 (46) 42.9 ± 7.6 (48) <0.000
Serine (µmol/l) 103.7 ± 17.3 (46) 109.8 ± 19.1 (48)   0.106
Lysine (µmol/l) 199.3 ± 31.8 (46) 186.3 ± 35.7 (48)   0.065
Glycine (µmol/l) 244.6 ± 48.7 (46) 213.0 ± 43.5 (48)   0.001
Glutamate (µmol/l) 37.4 ± 22.5 (46) 47.7 ± 20.3 (48)   0.021
Trp-ratio 9.0 ± 1.5 (46) 7.9 ± 1.5 (48) <0.000
Tyr-ratio 12.2 ± 3.3 (46) 11.3 ± 2.1 (48)   0.113
Neopterin (nmol/l) 20.4 ± 5.8 (43) 17.4 ± 3.7(28)   0.008
HVA (nmol/l)a 64.1 ± 16.5 (45) 53.2 ± 12.9 (41)   0.001
5-HIAA (nmol/l)b 43.5 ± 9.0 (45) 41.5 ± 12.9 (42)   0.405
a: HVA: homovanillic acid. b: 5-HIAA: 5-hydroxyindoleacetic acid
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Mircher et al.12. Although homocysteine was unfortunately not measured in this study, these data 
corroborate an altered homocysteine metabolism in persons with DS and are as such in line with 
the lowered plasma concentration of homocysteine reported by Progribna et al.29. Other investiga-
tors, however, reported increased concentrations of homocysteine31 32. As reviewed by Townsend 
et al.33, the sulphur containing amino acids methionine, homocysteine and taurine are involved in 
the maintenance and integrity of cellular systems by influencing cellular redox state and cellular 
capacity to detoxify toxic compounds, free radicals and reactive oxygen species. An imbalance of 
these amino acids in DS persons may indicate neuropathological changes in this group.
The increased Trp-ratio in the DS group suggests an enhanced availability of tryptophan for the 
synthesis of serotonin in the central nervous system. Whether central serotonergic neurotransmis-
sion is increased in DS persons cannot be concluded from this study, especially since the plasma 
concentration of 5-HIAA is not changed. The latter parameter, however, is only a very weak and 
indirect measure of central serotonergic activity34. On the other hand, plasma HVA concentra-
tions are significantly increased, which is an indication of a higher turnover of dopamine that was 
reported previously also in cerebrospinal fluid studies in persons with DS35, 36.
Neopterin is increased in the DS group as compared to controls. This finding is in agreement 
with the observations by Metha et al.15 who additionally reported that increase of neopterin is not 
correlated with age and sex. High concentrations of neopterin as seen in DS is consistent with the 
impaired immune function that was reported in persons with DS37, 38.
In conclusion, in the present study of persons with DS without any signs of dementia, somatic and/
or neuropsychiatric comorbidity and free of any medication, extensive biochemical abnormalities 
are found suggesting a compromised homocysteine metabolism, an activated cell-mediated im-
mune response and an enhanced turnover of dopamine. Interestingly, a few peripheral biochemi-
cal parameters appeared to have a marked potential to differentiate between DS persons from 
controls.
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AbstrAct
Persons with Down’s syndrome show an altered immune response and an increased susceptibility 
to Alzheimer’s disease. In a prospective study, we examined whether the plasma neopterin level, 
a marker for cell mediated immune activation and inflammation, is associated with an increased 
risk of dementia in persons with Down’s syndrome.
Plasma concentrations of neopterin were determined in a population-based study of 506 persons 
with Down’s syndrome, who were screened annually for dementia. We used Cox proportional 
hazards models to determine risk of dementia. 
Demented persons with Down’s syndrome have a significantly (p = 0.05) higher plasma neopterin 
concentration than the non-demented. In those without autoimmune disorders, or dementia at 
baseline (n = 259), those with a plasma level of neopterin above median, the risk to develop de-
mentia increased to 1.83 (95% confidence interval = 1.04-3.20). High plasma neopterin level is an 
independent determinant of the risk of dementia in persons with Down’s syndrome.
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introduction
Down’s syndrome (DS) is a common genetic disorder affecting about 1 in 750 live births in the 
general population. It is caused by a complete, or occasionally partial, triplication of chromosome 
21, which explains the increased risk of Alzheimer’s disease (AD). Despite the relatively uniform 
cause of dementia in persons with DS, patients with dementia show a large spread in the onset age 
of dementia. This can vary from age 35 to 70 years which suggests other risk factors may modify 
the onset of disease1. Persons with DS also show an altered immune response and an increased 
susceptibility to infectious diseases and immune mediated and aging-associated diseases2.
Among the various pathophysiological mechanisms involved in dementia in the general popula-
tion, inflammation and immune system activation are considered to play an important role in the 
development and progression of dementia3. Increased concentrations of immune activation mark-
ers, including C-reactive protein (CRP), tumor necrosis factor-α and neopterin, were reported 
in the brain but also in the blood of patients with AD and other neurodegenerative disorders4, 
5. While plasma levels of CRP may reflect an acute phase reaction, plasma neopterin levels are 
more likely to reflect cell mediated immune activation and inflammation4. In a previous study we 
found, in healthy persons with DS, aged 45 years and older, an increased plasma concentration of 
neopterin6. It is unknown whether plasma neopterin levels are associated with AD in persons with 
DS or with the onset of disease. The aim of this study is to investigate whether plasma neopterin 
levels in persons with DS are associated with the risk of dementia. 
methods
study population
We conducted a study of 506 persons with DS, aged 45 years and older, who were enrolled from 
December 1, 1999 to December 1, 2003 in a community-based study on DS and ageing in the 
Netherlands. Informed consent procedures and recruiting of subjects have been described in detail 
elsewhere1. All participants were assessed once yearly until they either died (n = 109), or were 
withdrawn from the study by their representatives (n = 7), up to the reference date of 1 January 
2007. At the time of study entry, each person received a complete assessment including interviews 
with relatives, carers and the general practitioner. All medical records were reviewed to disclose 
past or present medical disorders, such as epilepsy and depression, and the possible use of drugs. 
The same questionnaires and interviews were used annually from 1999-2007. All persons under-
went a general physical and neurological examination. Venous blood samples were taken fasting 
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in the morning. From the 506 participants in the total study of dementia and mortality in DS, 
plasma concentration of neopterin was measured in 394 (77.9%) persons who consented to give 
(sufficient) blood.
clinical assessments
Pre-morbid severity of intellectual disability (ID), based on medical records, was classified using 
the International Classification of Diseases7. According to these criteria, 136 (34.5%) of the par-
ticipants had a severe to profound level of ID, 211 (53.6%) had a moderate to mild level of ID. The 
severity of ID was not known for 47 (11.9%) participants. All persons were assessed for AD using 
the ICD-107 criteria and according to the guidelines produced by an international consensus panel 
established under the auspices of the Ageing Special Interest Group of the International Associa-
tion for the Scientific Study of Intellectual Disabilities (IASSID)8. The diagnosis of dementia was 
supported using the Dementia Questionnaire for persons with an intellectual disability (DMR)9, 10 
and the Social Competence Rating Scale for persons with an intellectual disability (SRZ)11. Persons 
who were not demented at baseline were screened annually. Those who fulfilled the criteria for 
AD, at baseline or during follow-up, were followed more intensively at 6-month intervals. These 
patients also received a clinical work-up, to exclude other physical and psychiatric factors as the 
possible cause of deterioration.
The history of past or current disorders as epilepsy, thyroid disorders, celiac disease, diabetes type 
1 and 2 and others were ascertained by reviewing the medical records. Information on causes of 
death was obtained from relatives or primary carers and supplemented with additional data from 
medical or autopsy records.
measurements
Neopterin
Immediately after venapuncture, plasma was prepared by a 20-min centrifugation step at 2650 
g and stored at −80°C. The concentration of neopterin in plasma was measured, blind to the de-
mentia status, after acid oxidation as described earlier12, 13. In short, 0.1 ml 1 M trichloroacetic 
acid was added to 0.4 ml of plasma, followed by 0.05 ml iodine solution (0.5% I2, 1% KI in 0.2 M 
trichloroacetic acid). After standing for 60 min under reduced light, excess iodine was reduced 
by the addition of 20 μl of 1% ascorbic acid solution and the mixture was centrifuged at 12 000 g 
for 15 min at 4°C. The supernatant (0.4 ml) was transferred to an amber glass vial, and 10 μl was 
injected onto a Hypersil C18 column (2.1×200 mm, 5 μm) using an HPLC system and fluorescence 
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detection (Agilent, Series 1100). The separation was achieved using an aqueous 15 mmol/l potas-
sium phosphate buffer, pH 6.45, and a stepwise eluant gradient with methanol (from 1.5 to 2 min 
to 10%, from 4 to 5 min to 100%, and from 6 to 8.3 min to 0%). Total run time was 14 min, the 
flow rate was set at 0.4 ml/min, the column temperature was 50°C, and the excitation and emission 
wavelengths were 360 and 440 nm, respectively. 
APOE
DNA was isolated, according to the salting out procedure as described by Miller et al.14. APOE 
genotypes were determined on 5ng/μl dry DNA samples using Taqman allelic discrimination 
technology15 on an ABI Prism 7900HT Sequence Detection System with SDS v 2.1 (Applied Bio-
systems, Foster City, CA). APOE genotyping was obtained blind to all clinical information.
statistical analysis
In the descriptive analyses, data were reported as mean ± standard deviation (SD). Because not 
all of the data sets showed normal distribution, the non-parametric Mann-Whitney U test was 
used to compare subgroups and the Spearman rank correlation analyses (ρ) to assess correlations. 
Neopterin measurements took place in three separate runs and although the means of these runs 
did not differ significantly (p>0.05), we adjusted in all analyses for the runs in our risk calculations. 
As there is no standardized reference for a normal range of plasma neopterin in persons with DS, 
the median value of neopterin was used in the subgroup as a cut-off point for defining ‘high’ level 
of plasma neopterin (> 21.20nM) versus ‘low’ level (< 21.20nM) of neopterin at baseline. To deter-
mine the cut-off, we used only Down persons without autoimmune disorders. The Kaplan-Meier 
life table methods and the Cox proportional hazards model was used to estimate the hazard ratio 
(HR) (with 95% confidence intervals (CI)) of dementia, adjusting for age at entry, gender and the 
presence of the APOEε4 allele. The time to event variable was follow-up time until reference date, 
death or the incidence of dementia. Statistical analysis was performed using the SPSS statistical 
package, version 11.0. 
results
The mean concentration of plasma neopterin, in the total population, was 25.18nM (range 4.58- 
90.10nM). The median concentration was 22.61nM. Table 1 shows the general characteristics of 
this study population. Persons born before 1947, aged 60 years and above at the reference date, 
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Table 1 The association of plasma neopterin levels with general characteristics and clinical outcomes
Total population Without autoimmune disorders
Number neopterin nM 
(SD)
p-value number neopterin nM 
(SD)
p-value
All 394 259
Age
  Born before 1947 88 28.26 (11.4)* 54 27.99 (10.2)*
  Born after 1947 306 24.29 (10.7) <0.001 205 22.29 (8.7) <0.001
Gender
  Female 148 26.50 (12.6) 89 25.01 (8.2)
  Male 246 24.38 (9.8) 0.19 170 22.67 (8.2) 0.14
Intellectual Disability
  Severe/profound 136 25.98 (11.9) 87 24.50 (9.5)
  Mild/moderate 211 24.82 (10.3) 0.57 130 22.48 (8.4) 0.14
Dementia status
  Non-demented 256 24.37 (10.3)* 162 22.26 (8.6)*
  Demented 138 26.68 (12.1) 0.05 97 25.50 (10.1) 0.007
  Prevalent dement 60 28.16 (14.3) 36 25.21 (10.3)
  Incident dement 78 25.55 (9.9) 0.50 61 25.67 (10.1) 0.61
Vital status
  Alive at reference date 315 24.77 (10.8) 208 22.84 (9.1)*
  Dead at reference date 79 26.81 (11.7) 0.09 51 26.07 (9.9) 0.03
APoEε4 allele
  Absent 281 25.20 (10.9) 185 23.74 (9.6)
  Present 110 24.95 (11.24) 0.09 71 22.46 (8.3) 0.35
Congenital heart disease
  Absent 300 24.27 (10.1) 231 23.35 (9.3)
  Present 36 27.09 (15.8) 0.76 26 24.91 (10.4) 0.65
Thyroid disorder
  Absent 247 23.29 (9.4)* -
  Present 90 27.48 (11.9) 0.003 -
Diabetes
  Absent 332 24.42 (10.3) -
  Present 5 21.57 (6.2) 0.70 -
Epilepsy
  Absent 249 24.47 (10.6) 194 23.64 (6.5)
  Present 86 25.0 (11.8) 0.99 63 23.06 (9.1) 0.62
Smoking
  Non-smoker 334 25.66 (11.5)* 210 24.09 (9.9)
  Smoker 60 22.49 (7.4) 0.05 43 20.64 (5.3) 0.06
Reference date: 01-01-2007
neopterin nM (SD): mean concentration neopterin at baseline ( Standard Deviation)
* p-value: Mann Whitney U-test, significance at 0.05 level
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1 January 2007, had significantly higher neopterin concentrations than the younger ones. Plasma 
neopterin concentrations were significantly higher in the demented persons (n = 138, 26.68 ± 
12.06nM) compared with the non-demented persons (n = 256, 24.37 ± 10.32nM; U = 15614, p = 
0.05). Further, neopterin levels were found to be significantly increased in non-smokers (n = 334, 
25.66 ± 11.46) compared with the smokers (n = 60, 22.49 ± 7.45; U = 8441, p = 0.05). As was to 
be expected, plasma neopterin concentration was significantly higher in persons with a history of 
autoimmune thyroid disorders (n = 90, 27.48 ± 11.9nM) than in persons without (n = 247, 23.29 
± 9.4; U = 8784, p = 0.003).
There were 78 cases of incident dementia diagnosed during 4.5 years of follow-up (minimum 0.0-
maximum 7.6 years). No significant differences in neopterin concentrations were found between 
the prevalent demented (n = 60, 28.2 ± 14.3nM) and those who developed dementia during follow 
up (n = 78, 25.6 ± 9.9nM; U = 2185, p = 0.50). 
To correct for the influence of autoimmune disorders, we excluded in the analyses all persons (n 
= 135) known to have autoimmune disorders, including thyroid disorders (n = 90), diabetes (n = 
5) and celiac disease (n = 3), and with unknown autoimmune status, leaving 259 persons in the 
analyses (Table 1). Due to the increased prevalence of auto-immune disorders in women, persons 
excluded from this selection were more frequently women (46.8 versus 34.3%, p = 0.05). The mean 
concentration of neopterin after exclusion of those with auto-immune disorders was 23.47nM 
(range 4.58-62.20); while the median concentration was 21.20nM. The difference between the de-
mented and non-demented persons increased compared to that seen in the total study population 
(p = 0.007). There is a significant correlation between neopterin concentration and dementia in 
this subgroup: ρ = 0.17, p = 0.007, as well as between neopterin and age: ρ = 0.22, p<0.001, and the 
vital status: ρ = 0.14, p = 0.03. 
When excluding in the analyses those persons with known autoimmune disorders, the risk of 
developing dementia was almost two times increased: 1.83, (95%CI = 1.04-3.20) in the subgroup 
with plasma neopterin levels above median (> 21.20 nM)(figure 1).
The absolute risk of disease increases from 17 % in those with a plasma neopterin levels < 21.20nM 
to 30% in those with a neopterin level > 21.20nM. When excluding those with auto-immune dis-
orders, mortality was also associated with increased neopterin levels (p = 0.03). This is expected as 
dementia is the main cause of death.
The Cox-analysis was repeated in the non-smoking persons only (n = 210), with 52 persons who 
developed dementia. The risk of developing dementia, in the group with the highest level of neop-
terin, adjusting for age, gender and the APOEε4 allele, increased to 2.10, (95%CI = 1.12-3.92). 
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discussion
To the best of our knowledge, this is the first study in which a relation between plasma concentra-
tion of neopterin and (risk of) dementia in persons with DS is described. Compared with the 
persons with DS without dementia, the prevalent demented persons with DS, and those persons 
who were non-demented at baseline but who developed dementia during the follow-up, had sig-
nificantly higher plasma neopterin concentrations at the start of the study. There was no significant 
difference in the concentrations between the incident patients who developed dementia during 
follow-up and the prevalent demented cases (p = 0.50). When excluding in the analyses those 
persons with known autoimmune disorders, the risk of developing dementia was almost two times 
increased: 1.83, (95%CI = 1.04-3.20) in the subgroup with plasma neopterin levels above median 
(> 21.20nM).
Neopterin, produced by interferon-γ-activated monocyte-derived macrophages and dendritic 
cells, is a reliable and sensitive indicator of cell-mediated immune activation16. In our previous 
study increased neopterin concentrations were found in healthy persons with DS compared with 
controls in the general population6.
The comorbidity associated with activation of the immune system is high in elderly persons and 
these disorders may explain part of the high plasma neopterin levels. The plasma neopterin con-
centration was higher in persons with thyroid dysfunction. There was indeed a significant dif-
ference between neopterin concentrations in the healthy group compared to those with hypo-or 
hyperthyroidism. We therefore evaluated the risk of developing dementia excluding those persons 
known to have autoimmune disorders. The association remained statistically significant. Smoking 
Figure 1 Cumulative incidence (%) of dementia during follow-up in those with no autoimmune disorders
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had also a significant effect on the neopterin concentration, which is in agreement with earlier 
studies in healthy adults17, 18. While plasma CRP levels are significantly increased in smokers19, 
plasma neopterin levels are decreased in our study of DS and others in the general population17, 18. 
This observation has been explained by a suppressive effect of tobacco products on the immune 
system, which may lead to lower neopterin production in smokers. Also when limiting the analysis 
to non-smokers, we found those with a high plasma neopterin level to have a significantly higher 
risk of developing dementia. 
Although our study is relatively small, it is the largest longitudinal follow-up study of persons with 
DS in which participants were clinically examined in person. A major advantage of the longitu-
dinal design is that the outcome of prevalent and incident demented patients can be compared. 
By limiting the analysis to incident patients, who are disease free at baseline, we can conduct an 
unbiased study of the risk of dementia for a determinant such as plasma neopterin, which may be 
altered by the disease status. Although the incident demented patients had a lower (25.55 ± 9.9nM) 
concentration of neopterin at baseline than the prevalent demented patients (28.16 ± 14.3nM), the 
groups did not differ significantly. 
Persons with DS are at increased risk of dementia and AD. We have shown earlier in our popula-
tion-based study that, from the age of 45 years onwards, the overall prevalence of AD was 16.8%1. 
The risk of dementia is an important question for relatives and carers. Here we show that the 
absolute risk is over 30% in those with a neopterin level > 21.20nM. Our prospective follow-up 
study indicates that elevated plasma concentration of neopterin in non-demented persons with DS 
is an independent determinant of the risk dementia. 
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AbstrAct
Subjects with Down’s syndrome (DS) have abnormalities in virtually all aspects of the immune 
system and almost all will be affected with Alzheimer’s disease (AD). It is thought that nitric oxide 
(NO) is involved in the pathophysiology of AD. In addition, the immune activation marker neop-
terin is increased in AD patients.
In the present study including a total of 401 elderly DS subjects, the spectrum of plasma amino 
acids and neopterin was investigated and related to development of AD.
Concentrations of nearly all amino acids in DS subjects differed significantly from those of healthy 
controls. Neopterin was increased in DS subjects, especially in dementia. The production of NO as 
reflected by an increased citrulline/arginine ratio was enhanced during development of clinical de-
mentia. Neopterin concentrations correlated to the NO production only in the group of demented 
subjects (ρ = 0.48, p<0.000).
The results of this study are suggestive for an increase in oxidative processes in DS subjects with 
AD. 
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introduction
Down’s syndrome (DS) is a common genetic disorder with a prevalence of 1:750 and is caused by a 
complete or occasionally partial triplication of chromosome 21. Its prevalence is highly dependent 
on maternal age at gestation. It is well known that individuals with DS have an increased rate of 
congenital and acquired medical complications including among others thyroid gland dysfunc-
tion. In addition, abnormalities have been reported in virtually all aspects of the immune system 
resulting in a greater susceptibility to infectious disease. Finally, they have a higher risk for hae-
matological malignancies, particularly leukaemia’s, and virtually all show the neuropathological 
changes of Alzheimer’s disease (AD) by the age of 35 to 40 years. This may be due to an increased 
production of the amyloid precursor protein1, 2. Onset of clinical dementia is in general in the first 
half of the sixth decade. With respect to psychopathology, depression is frequently diagnosed and 
shows an age related increase3.
A growing body of evidence indicates that there is an increased oxidative stress in AD brains 
and it is hypothesised that nitric oxide (NO) can be related to many of the pathophysiological 
mechanisms of AD4, 5. The presence of any stimulant that leads to an overproduction of NO will 
probably cause neuronal damage6. The biologically active molecule NO is formed by the conver-
sion of L-arginine to L-citrulline, a reaction catalyzed by the enzyme nitric oxide synthase. In this 
process tetrahydrobiopterin (BH4) is a necessary cofactor. The ratio of the plasma concentrations 
of citrulline (Cit)-and arginine (Arg), the so-called Cit-Arg ratio, is regarded as an index of NO 
synthesis7.
Brain inflammation is mainly caused by activation of glia cells that produce a variety of pro-inflam-
matory and neurotoxic factors, including free radicals such as NO8, 9. Inflammation and immune 
system activation are considered to play an important role in the development and progression of 
dementia10. Neopterin, as indicator for this activation process, is found to be increased in the brain 
and the plasma of patients with AD and other neurodegenerative disorders11, 12.
It has become clear that amino acids are not only essential for various metabolic pathways such as 
the synthesis of the major neurotransmitters, but also for maintenance of cell structure and func-
tionality of many organs. In addition, amino acids are involved in immune responses13, 14. Probably 
of special relevance are the co-called branched-chain amino acids (BCAA) that comprise the three 
essential amino acids: l-leucine, l-isoleucine and l-valine. In experimental conditions, administra-
tion of BCAA was found to improve immune function15. In a previous study with healthy DS 
individuals, wide spread differences in nearly all amino acids were found as compared to healthy 
control subjects with significant lower levels of the essential amino acids16.
The present study was designed to assess the spectrum of amino acids and the role of NO and 
BCAA in a large cohort of DS individuals with and without dementia.
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methods
study population
Over a period of 4 years a community based sample of 401 individuals with DS, age 45 years and 
older, from the Southern and South-Western part of the Netherlands was composed. Recruitment 
procedures and the ethical protocol are described in detail elsewhere17,18. The sample comprises 
151 women and 250 males with a mean age of 52 (SD 5.1) years (Table 1). In 232 subjects DS was 
confirmed by cytogenetic analysis. In the remaining, the diagnosis was based on the characteristic 
phenotype.
The study population was divided into two birth cohorts based on the subject’s age at the refer-
ence date. The birth cohorts distinguishes patients who were 60 years or older (born before 1947; 
n = 88) and those who were younger than 60 years (born after 1947; n = 313). Separate analyses 
were performed comparing individuals who were demented at baseline (prevalent demented) with 
those who developed dementia at follow-up (incident demented).
Table 1 Characteristics of the study group
All Healthya Dementedb Depressivec Epilepticd
All 401 130 84 38 34
Sex, n (%)
  women 151 (37.7) 41 (31.5) 32 (38.1) 19 (50) 11 (32.4)
  men 250 (62.3) 89 (68.5) 52 (61.9) 19 (50) 23 (67.6)
Age start, mean (SD) 51.6 (5.1) 49.9 (3.9) 53.2 (5.7) 50.3 (3.3) 51.3 (4.5)
Level of intellectual disability, n (%)
  Severe to profound 138 (34.4) 40 (30.8) 34 (40.5) 15 (39.5) 13 (38.2)
  Mild to moderate 216 (53.8) 68 (52.3) 46 (54.8) 18 (47.4) 17 (50)
Living situation, n (%)
  Institutionalised 247 (61.6) 79 (60.8) 50 (59.5) 32 (84.2) 22 (64.7)
  Community Living 154 (38.4) 51 (39.2) 34 (40.5) 6   (15.8) 12 (35.3)
Dementia status, n (%)
  Prevalent demented 61 (15.2) 30 (35.7)
  Incident demented 79 (19.7) 54 (64.3)
a healthy subjects without dementia or symptoms of depression and/or epilepsy
b demented subjects without symptoms of depression and/or epilepsy
c depressive subjects without symptoms of dementia and/or epilepsy
d subjects with epilepsy, without dementia and/or depressive symptoms
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clinical assessment
At baseline, assessment included an extensive interview with relatives, caregivers and the respon-
sible physician in order to ascertain the medical history and daily functioning. In addition, all 
subjects had a thorough physical and neurological examination.
The level of premorbid intellectual disability (ID) was derived from the medical records and clas-
sified according to the ICD-1019. In addition, a diagnosis of AD was made based on the ICD-10 
criteria and the guidelines of the IASSID20. All subjects were screened annually with a mean follow-
up of 4.5 years. Patients, who met the diagnostic criteria of AD at baseline or during follow-up, 
were monitored every 6 months.
A probable diagnosis of depressive disorder was made by the responsible physician or the 
consultant psychiatrist. Epilepsy was diagnosed by a neurologist or the responsible physician. 
Level of ID and living situation as an expression of general functioning are presented in 
Table 1. 
The study population was divided into 4 subgroups according to the presence of only dementia (n 
= 84), only depression (n = 38) or only epilepsy (n = 34) and healthy DS individuals (n = 130).The 
ratio for this sub-classification was that the use of anti-epileptics and antidepressants might bias 
the results. At baseline, of the 401 DS subjects included in this study, 87 had a diagnosis of epilepsy 
and 38 of dementia resulting in a group of 276 non-demented subjects at the start of the study.
biochemical analyses
Plasma amino acids were analyzed by high-performance liquid chromatography (HPLC) using 
pre-column derivatization with o-phthaldialdehyde phthaldialdehyde17. The tryptophan-ratio was 
calculated by dividing the total tryptophan level times 100 by the sum of the other large neutral 
amino acids (LNAA), i.e. valine, isoleucine, leucine, tyrosine (Tyr) and phenylalanine (Phe), which 
compete for the transport of tryptophan through the blood-brain barrier. The tyrosine-ratio was 
calculated in the same manner by substituting tryptophan for tyrosine. The value of aromatic 
amino acids (AAA) comprises the summed concentrations Phe, Tyr and tryptophan, and the value 
of branched chain amino acids (BCAA) is the sum of the concentrations of leucine, isoleucine and 
valine. The Phe-Tyr ratio was calculated to serve as an estimate of BH4 activity. Plasma concentra-
tion of neopterin was determined as described previously18. 
Amino acids could be measured in 401 subjects and neopterin in 394 subjects.
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statistical analysis
Univariate analyses of variance and chi-square analyses were used to determine whether missing 
data were associated with age, sex, and level of ID; no significant effects were found. To define 
syndrome specific differences, a subgroup of healthy subjects with DS (n = 130) was compared 
with a group of 48 age and sex matched healthy controls of the general population. For neopterin, 
data were available for 28 control subjects. In descriptive analyses, data were reported as means 
or numbers. Not all data showed normal distribution, and therefore statistical analyses were made 
using the nonparametric Mann-Whitney U test for comparison of groups. When analysed as con-
tinuous variables, as in the partial correlation analyses (ρ), variables were natural log transformed. 
P values were corrected for multiple comparisons.
results
During the follow-up period a total of 80 subjects died. As can be inferred from table 2, values 
of virtually all amino acids and their ratios as well as of neopterin are significantly different in 
the group of healthy DS (n = 130) and the demented group (incident and prevalent: n = 140) as 
compared to normal controls (n = 48). Since the effect of anti-epileptics are restricted to the levels 
of tryptophan and the tryptophan ratio only, subjects with epilepsy were not excluded from the 
demented group.
Plasma concentrations of most amino acids are not different in the 4 subgroups (data not shown). 
Significant differences (p<0.05) are found for taurine and phenylalanine in that the levels of 
both amino acids are increased in the demented group as compared to the healthy group (55.4 ± 
12.3µmol/l versus 51.3 ± 12.0µmol/l; p = 0.02 and 62.5 ± 13.1µmol/l versus 58.7 ± 12.7µmol/l; p 
= 0.05). The increased level of taurine is present mainly in the incident demented group (incident 
demented: 56.6 ± 12.8µmol/l versus prevalent demented: 49.8 ± 11.8µmol/l; p = 0.003). In the 
epileptic subgroup only the tryptophan ratio is found to be decreased as compared to the other 
subgroups. 
In the group of prevalent demented subjects, excluding those with epilepsy (n = 38; including 8 
depressives), a significantly higher neopterin concentration 28.78 ± 14.4nmol/l versus 24.74 ± 
10.3nmol/l (p = 0.05) and a lower Cit-Arg ratio 0.56 ± 0.13 versus 0.64 ± 0.2 (p = 0.006) are found 
as compared to the group of non-demented subjects (n = 276). In the group of incident demented 
subjects, a significantly higher Cit-Arg ratio is found as compared to the group of prevalent de-
mented subjects (0.66 ± 0.2 versus 0.56 ± 0.1; p = .003). After adjusting for age, there is a high 
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correlation between neopterin and the Cit-Arg ratio in the group of demented subjects: ρ = 0.48; 
p< 0.000, but not in the non-demented: ρ = 0.06; p = 0.2. 
From table 3, it can be inferred that there is a significant age effect, in that the concentrations of 
neopterin and the tyrosine ratio are increased whereas the levels of BCAA, taurine and tryptophan 
are decreased in the older group. 
discussion
In the present study, including a large sample of DS subjects with or without dementia, plasma 
concentrations of nearly all biochemical parameters differ significantly from normal controls. The 
decreased tryptophan ratio is explained most likely by the frequent use of anti-epileptics. Concen-
trations of neopterin and the tyrosine ratio are increased with age whereas the levels of BCAA, 
Table 2 Values of biochemical parameters in healthy controls (n = 48), healthy persons with Down’s 
syndrome (n = 130) and demented persons with Down’s syndrome (n = 140)
parameter Healthy controls Healthy persons with 
Down’s syndrome
Demented persons with 
Down’s syndrome
Citrulline μM 34.23 (8.8) 45.89 (13.2)* 45.29 (13.9)*
Arginine μM 68.02 (24.3) 74.49 (21.1) 74.42 (19.3 )
Taurine μM 42.88 (7.6) 51.28 (12.0)* 54.31 (13.5 )*
Tyrosine μM 71.04 (17.3) 61.00 (15.2)* 62.95 (15.1)*
Valine μM 286.21 (59.7) 231.76 (60.6)* 235.78 (58.3)*
Methionine μM 32.04 (6.4) 24.99 (5.4)* 25.14 (6.7)*
Tryptophan μM 50.38 (9.1) 42.83 (9.4)* 40.38 (10.4)*
Phenylalanine μM 63.06 (9.9) 58.68 (12.7) 60.85 (13.3 )
Isoleucine μM 82.69 (24.1) 63.87 (17.0)* 64.61 (16.6)*
Leucine μM 148.48 (31.8) 125.97 (28.4)* 124.31 (27.8)*
Tryptophan ratio 7.89 (1.5) 8.07 (1.4) 7.47 (1.6)#
Tyrosine ratio 11.33 (2.1) 11.82 (2.4) 12.16 (2.5)*
Phe/Tyr ratio 0.9 1 (0.1) 0.98 (0.1)* 0.98 (0.1)*
Cit/Arg ratio 0.55 (0.2) 0.63 (0.2)* 0.62 (0.2)*
Neopterin nM 17.3 (3.6) 23.40 (8.7)* 26.68 (12.1)*#
BCAA μM 517.37 (111.2) 421.60 (103.8)* 424.69 (99.9)*
AAA μM 184.48 (30.2) 162.51 (34.1)* 164.17 (34.8)*
LNAA μM 701.85 (135.2) 584.11 (131.6)* 588.87 (126.3)*
* p<0.05 (Mann-Whitney U test); Subjects with DS, healthy and demented, compared with healthy controls
# p<0.05 (Mann-Whitney U test); Demented subjects compared with healthy DS subjects
Phe/Tyr ratio is the phenylalanine to tyrosine ratio; Cit/Arg ratio is the citrulline to arginine ratio.
BCAA= Branched Chain Amino Acids (valine + isoleucine + leucine); LNAA=Large Neutral Amino Acids (phenylalanine 
+ tyrosine + tryptophan + valine + isoleucine + leucine); AAA=Aromatic Amino Acids (phenylalanine + tyrosine + 
tryptophan).
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taurine and tryptophan are decreased in the older group. These findings are consistent with those 
reported previously in a small group of healthy DS subjects16.
With respect to neopterin, a marked increase is found in the total group as compared to normal 
controls, that further increases in the demented group. In the group of prevalent dementia the en-
hanced concentration of neopterin is significantly correlated with a decreased Cit-Arg ratio. This 
finding is suggestive for an increase in oxidative, inflammatory or neurodegenerative processes 
in dementia. An explanation for a decreased Cit-Arg ratio in this condition may be a reduced 
bioavailablity of BH4, which is the cofactor for NO synthesis and also for the conversion of pheny-
lalanine to tyrosine. Interestingly, the phenylalanine levels are also decreased in the demented DS 
subjects as compared to the healthy DS subjects. Possible mechanisms for the impaired bioavail-
ability of BH4 are oxidation of the labile substance BH4 due to the oxidative stress and/or deple-
tion of BH4 due to the higher neopterin synthesis at the expense of BH419, 20. Since the Cit-Arg 
ratio is significantly higher in the incident demented cases and assuming that this ratio is a good 
reflection of NO synthesis indeed, it can be hypothesized that the production of NO is enhanced 
during the early development of dementia.
Table 3 Mean concentrations of amino acids in two birth cohorts of persons with Down’s syndrome without 
epilepsy
parameter Born before 1947 (n=63) Born after 1947 (n= 251) p-value
Citrulline μM 46.71 (16.1) 45.49 (12.7) 0.50
Arginine μM 72.59 (20.2) 74.73 (22.1) 0.62
Taurine μM 49.68 (12.4) 53.22 (12.5) 0.03*
Tyrosine μM 61.05 (19.2) 62.51 (15.2) 0.45
Valine μM 218.32 (75.6) 238.07 (56.4) 0.03*
Methionine μM 25.06 (8.4) 25.36 (5.5) 0.38
Tryptophan μM 39.54 (10.6) 43.70 (9.1) 0.01*
Phenylalanine μM 59.54 (17.3) 61.01 (12.4) 0.64
Isoleucine μM 60.14 (20.6) 65.36 (17.3) 0.04*
Leucine μM 118.68 (35.6) 127.87 (28.1) 0.03*
Tryptophan ratio  7.90 (1.6) 8.01 (1.4) 0.73
Tyrosine ratio 12.59 (2.8) 11.81 (2.4) 0.01*
Phe/Tyr ratio 0.98 (0.1) 0.99 (0.2) 0.82
Cit/Arg ratio 0.65 (0.2) 0.63 (0.2) 0.14
Neopterin nM 28.96 (12.2) 24.27 (10.2) 0.00*
BCAA μM 397.14 (130.1) 431.30 (99.1) 0.03*
AAA μM 159.45 (42.6) 164.78 (34.3) 0.16
LNAA μM 557.27 (166.0) 598.52 (125.7) 0.06
* p<0.05 (Mann-Whitney U test)
For abbrevations of Phe/Tyr ratio, Cit/Arg ratio, BCAA, LNAA and AAA see legend to Table 2
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The plasma concentration of taurine is increased in the demented group especially in the subgroup 
of incident dementia. The finding of an increased level of taurine may be syndrome specific since 
similar observations have been reported previously14, 16, 21. It has been suggested that taurine may 
prevent neurotoxicity of beta-amyloid22 and may decrease beta-amyloid aggregation23. It is, how-
ever, not clear whether an increase of amyloid precursor protein in DS is associated with increased 
taurine plasma concentrations.
The BCAA concentration is not different in the various subgroups but decreases with age. Since 
several decades it has been suggested from animal studies that a lower plasma level of BCAA may 
result in immune impairment13, 24. Whether the observation of diminished BCAA in the group of 
older DS subjects reflects a syndrome specific impaired immune function is not clear. This may 
also be the consequence of dietary factors albeit that both in the present study as in the previous 
one18 a large difference between healthy controls and DS subjects was found in the BCAA levels.
In conclusion, the results of the present study demonstrate again that plasma levels of nearly all 
measured amino acids in DS subjects differ substantially from those in healthy controls. Moreover, 
in demented DS individuals an additional increase of taurine is observed, while during develop-
ment of clinical dementia changes in levels of biochemical parameters related to NO metabolism 
and oxidative stress occur. 
Chapter 3.3
126
REFEREnCES
1. Lockstone HE, Harris LW, Swatton JE, Wayland MT, Holland AJ, Bahn S. Gene expression profiling in the 
adult Down syndrome brain. Genomics.2007;90:647-660.
2. Cheon MS, Dierssen M, Kim SH, Lubec G. Protein expression of BACE1, BACE2 and APP in Down 
syndrome brains. Amino Acids.2007.
3. Hunter AGW. Down syndrome. New Yersey: Wiley-Liss; 2005.
4. Akomolafe A, Lunetta KL, Erlich PM, et al. Genetic association between endothelial nitric oxide synthase 
and Alzheimer disease. Clin Genet.2006;70:49-56.
5. Moreira PI, Santos MS, Oliveira CR, et al. Alzheimer disease and the role of free radicals in the pathogen-
esis of the disease. CNS Neurol Disord Drug Targets.2008;7:3-10.
6. Akyol O, Zoroglu SS, Armutcu F, Sahin S, Gurel A. Nitric oxide as a physiopathological factor in neurop-
sychiatric disorders. In Vivo.2004;18:377-390.
7. Fekkes D, Bannink M, Kruit WH, et al. Influence of pegylated interferon-alpha therapy on plasma levels 
of citrulline and arginine in melanoma patients. Amino Acids.2007;32:121-126.
8. Bernstein HG, Heinemann A, Krell D, et al. Hypothalamic nitric oxide synthase in affective disorder: focus 
on the suprachiasmatic nucleus. Cell Mol Biol (Noisy-le-grand).2005;51:279-284.
9. Sharma JN, Al-Omran A, Parvathy SS. Role of nitric oxide in inflammatory diseases. 
Inflammopharmacology.2007;15:252-259.
10. McGeer PL, McGeer EG. Inflammation and the degenerative diseases of aging. Ann N Y Acad 
Sci.2004;1035:104-116.
11. Hull M, Pasinetti GM, Aisen PS. Elevated plasma neopterin levels in Alzheimer disease. Alzheimer Dis 
Assoc Disord.2000;14:228-230.
12. Murr C, Hainz U, Asch E, et al. Association of increased neopterin production with decreased humoral 
immunity in the elderly. Exp Gerontol.2003;38:583-587.
13. Li P, Yin YL, Li D, Kim SW, Wu G. Amino acids and immune function. Br J Nutr.2007;98:237-252.
14. Mircher C, Salabelle A, Peeters MA, et al. [Variation of amino acids in relation to age in Down syndrome 
subjects]
 Variation des acides amines en fonction de l’age chez des sujets trisomiques 21. Arch Pediatr.1997;4:1093-
1099.
15. Kakazu E, Kanno N, Ueno Y, Shimosegawa T. Extracellular branched-chain amino acids, especially valine, 
regulate maturation and function of monocyte-derived dendritic cells. J Immunol.2007;179:7137-7146.
16. Coppus AW, Fekkes D, Verhoeven WM, Tuinier S, Egger JI, van Duijn CM. Plasma amino acids and 
neopterin in healthy persons with Down’s syndrome. J Neural Transm.2007.
17. Fekkes D, van Dalen A, Edelman M, Voskuilen A. Validation of the determination of amino acids in 
plasma by high-performance liquid chromatography using automated pre-column derivatization with o-
phthaldialdehyde. J Chromatogr B Biomed Appl.1995;669:177-186.
18. Hoekstra R, van den Broek WW, Fekkes D, Bruijn JA, Mulder PG, Pepplinkhuizen L. Effect of electro-
convulsive therapy on biopterin and large neutral amino acids in severe, medication-resistant depression. 
Psychiatry Res.2001;103:115-123.
19. Shi W, Meininger CJ, Haynes TE, Hatakeyama K, Wu G. Regulation of tetrahydrobiopterin synthesis and 
bioavailability in endothelial cells. Cell Biochem Biophys.2004;41:415-434.
20. Ploder M, Neurauter G, Spittler A, Schroecksnadel K, Roth E, Fuchs D. Serum phenylalanine in patients 
post trauma and with sepsis correlate to neopterin concentrations. Amino Acids.2007.
nitric oxide, amino acids and neopterin
127
21. Coppus AW, Fekkes D, Verhoeven WM, Tuinier S, Egger JI, van Duijn CM. Plasma amino acids and 
neopterin in healthy persons with Down’s syndrome. J Neural Transm.2007;114:1041-1045.
22. Louzada PR, Lima AC, Mendonca-Silva DL, Noel F, De Mello FG, Ferreira ST. Taurine prevents the neu-
rotoxicity of beta-amyloid and glutamate receptor agonists: activation of GABA receptors and possible 
implications for Alzheimer’s disease and other neurological disorders. FASEB J.2004;18:511-518.
23. Santa-Maria I, Hernandez F, Moreno FJ, Avila J. Taurine, an inducer for tau polymerization and a weak 
inhibitor for amyloid-beta-peptide aggregation. Neurosci Lett.2007;429:91-94.
24. Jose DG, Good RA. Quantitative effects of nutritional essential amino acid deficiency upon immune re-
sponses to tumors in mice. J Exp Med.1973;137:1-9.

Chapter 4
General Discussion

General Discussion
131
introduction
The last decades have shown a distinct trend of improved survival in persons with Down’s syn-
drome (DS)1. The life expectancy increased from 9 years of age in 1929 to 12 years in 1949, and 49 
years in 19972. In developed countries recent estimates indicate an average age of death of above 
50 years3-7. Survival in the first year of life has shown particular improvement and for recently 
born cohorts at least 92% of the children with DS will live to 1 year of age and 90% up to 10 years5, 
8, 9. Glasson (2002) found that in a follow-up cohort of 1332 persons with DS in Australia, of all 
ages, approximately 25% of all deaths occurred between the ages of 58 an 63 years5. Day et al.10 
investigated mortality and causes of death between 1988 and 1999 in 14781 persons with DS in 
California. During the study period mortality declined, especially for children with congenital 
heart defects, due to successful medical treatment1, 2. However, no significant decline was observed 
in adult mortality. The elderly persons with Down syndrome at present, are derived from cohorts, 
born between 1940 and 1950. This makes it difficult to predict whether the more recently born co-
horts will also show an increased mortality of around the age of 60 and requires in depth research. 
Limited information is available on the timing and the consequence of the comorbidities affecting 
persons with DS as they age. Conditions as obesity, mobility restrictions, visual and hearing im-
pairment, depression, hypothyroidism, cardiovascular diseases, epilepsy and Alzheimer’s disease 
are known to become increasingly prevalent in later life11-13, but as yet their effect on mortality risk 
is not well described. In this thesis we have focused on Alzheimer’s disease (AD) as it is reported 
to be the main predictor of morbidity and mortality in elderly persons with DS.
dementiA
Prevalence of dementia
Alzheimer’s disease (AD) is the most important cause of morbidity and mortality among elderly 
DS persons. The prevalence of clinical AD has been examined extensively14-35. Prevalence rates 
have varied from 4% in a community sample11 to 88% in an institution-based sample24. In our 
longitudinal population based study, the overall prevalence of dementia was 16.8%. The prevalence 
of dementia increased from 8.9% in the 45 to 49-age category to 32.1% in the 55 to 59-age category, 
but dropped in the oldest group (60 years and older) to 25.6% (see chapter 2.1). These results were 
consistent with other population-based prevalence studies22, 25, 29, 31, 32, 34-39. All studies showed an 
exponential increase in prevalence with age, up to the age of 60 years.
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Before interpreting the findings, a methodological issue, which needs to be discussed, is the 
validity of the diagnosis AD. Although there are now well-accepted criteria for the diagnosis of 
dementia in adults with intellectual disability40, 41, which we have used, the diagnosis of dementia 
remains difficult, both in research setting as well as in clinical practice. For the present study, 
persons were systematically screened for dementia, annually during follow-up, and examined in 
person, making differences in diagnostic criteria across patients unlikely. The demented patients in 
this study met the ICD-10 criteria had an insidious progressive course of the disease. A diagnostic 
panel discussed all diagnoses. We further, followed all patients, to exclude misdiagnosis such as 
depression. This is in particular relevant for patients diagnosed with possible dementia. All per-
sons except one progressed in time from a diagnosis of possible dementia to a definite dementia, 
which underscores the validity of our diagnosis. However, in only a few cases, the diagnosis was 
confirmed by autopsy.
An interesting finding in our population-based study is that we observed that, despite the exponen-
tial increase in prevalence with age, the prevalence of dementia decreases in the oldest group and 
does not exceed 25.6%. This is substantially lower than expected based on literature31, 39. Previous 
studies varied considerably in the populations studied, design of the study, and in the size of the 
population studied (see chapter 2.1). Studies conducted with institutionalised patients may have 
been biased in that they included a selection of more severely intellectually disabled or demented 
patients. Another major limitation of the previously listed studies is their small size, varying from 
50 to 307 subjects. The most important problem is that previous studies only included a small 
number of elderly DS persons (aged 60 years and above), which limited the interpretation and 
analysis of the prevalence of AD in the oldest age group. Our population-based study included 
118 persons with DS over 60 years, which were examined in person, making it one of the largest 
studies conducted to date.
There is an ongoing debate on the percentage of DS persons that will eventually develop dementia 
in old age. Several studies, mostly neuropathological, suggested that all patients develop AD19, 42-45. 
Our study, including persons up to the age of 77 years, strongly argues against a full penetrance of 
AD. The eldest, those in the age category of 60 and above, are the survivors that escaped dementia. 
Probably there are other factors, genetic and/or environmental, that protect them against develop-
ing dementia before this age. Further research is required to investigate the age-associated preva-
lence of dementia in persons with DS. Another issue to be examined further will be the incidence 
of Alzheimer’s disease and the relation to morbidity and mortality. In our studies, the number of 
patients studied was too small to allow valid age specific incidence rates (see chapter 2.1, Table 3). 
This will be an important target for the near future in our research plan.
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Predictors of dementia in down’s syndrome
APOE
In the general population, the apolipoprotein E (APOE) gene on chromosome 19 modulates the 
risk of AD in some studies46-48. The ε4 allele of APOE is associated with an earlier onset age and 
increased risk of AD. On the contrary the APOE ε2 allele may reduce the risk of dementia in 
heterozygous carriers. In persons with DS, a large variation of the APOE allele frequencies has 
been found49-51, most likely reflecting the different geographic origins. The relationship between 
APOE ε4 and the risk and onset of AD in persons with DS has been controversial. Some studies 
showed an increased risk of AD associated with the APOE ε4 allele in persons with DS52-57, but 
others could not confirm this50, 51, 58. There is evidence that APOE ε2 is associated with a protective 
effect on AD33, 59, 60 but this could not be confirmed by all studies52, 57. 
In our study, in 425 persons with DS aged 45 years and older, we found overall a modest but not 
statistically significant effect of APOEε4 on the prevalence of dementia (Odds Ratio (OR): 1.57, 
95% CI = 0.87-2.82). We did not find an effect of APOEε4 on the age of onset of AD. When pooling 
our data in a meta-analysis with all earlier studies of prevalent patients35, 50, 52-54, 59-62, the APOEε4 
allele shows a significant 1.59-fold, (95%CI = 1.19-2.12) increase in risk of dementia in persons 
with DS. We divided the meta-analysis up into a “ younger age group”33, 35, 53, 60, 61 and an “older age 
group”50, 52, 54, 59, 63. The effect of APOE ε4 in the younger age group (younger than 50 years) was 
not significant: OR: 1.49, (95%CI = 0.84-2.65). Only in the older age group there was a significant 
relation between the presence of the APOE ε4 allele and dementia: OR: 1.62, (95%CI = 1.15-2.29) 
(see chapter 2.2). In our study population, we did not find a detectable association between APOE 
ε2 and AD.
The findings of our meta analysis suggest that APOE ε4 determines the prevalence of AD in per-
sons with DS. These findings are consistent with those of the general population46, 47, 64 where a 
strong and consistent association between the presence of an APOE ε4 allele and risk for AD has 
been established. Our population based study and meta-analyses suggest that the effect of APOE 
ε4, increased the prevalence of dementia in persons with DS, by 1.6 times. APOE ε4 may interact 
with the amyloid-beta(Aβ) peptide to increase amyloid aggregation. The presence of an APOE ε4 
allele was associated with increased plasma levels of Aβ1-42, in both nondemented and demented 
persons with DS, as described by Schupf et al.65. The effect of the APOE ε4 allele on Aβ1-42 levels 
may be related to acceleration of the rate of amyloid fibril formation. 
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Age at menopause
Although data are scarce, women with DS appear to reach menopause at an earlier age than wom-
en in the general population56, 66-68. The results in these studies suggest that the earlier menopause, 
including the reduction in estrogens following menopause, contributes to the earlier onset and 
increased risk of AD in women with DS69-71. In our prospective study cohort of 85 postmenopausal 
women, we found that the mean age of menopause is relatively early (44 years) compared to that 
seen in the general population (51.4 years)72. Age at menopause is significantly correlated with 
age at diagnosis of dementia (ρ = 0.52; p< 0.001), as well as with risk of dementia: Hazard Ratio 
(HR): 1.82 (95%CI = 1.31-2.52) (see chapter 2.4). Based on these findings we concluded that age at 
menopause in women with DS is a determinant of age at onset of dementia. 
An important methodological problem is that many women with DS in the Netherlands use oral 
contraceptives, making it impossible to determine age at natural menopause. Similar to the prob-
lems encountered in other studies, it was difficult for many women in our study to pinpoint the age 
at menopause. Information bias cannot be excluded as we were able to determine the exact age of 
natural menopause in only 85 (55 %) of the postmenopausal women. It is also possible that selec-
tion bias has occurred prior to study entry, since women with a very early menopause and women 
with an APOEε4 allele may have a higher risk to develop dementia and to die before entry into the 
study. Nevertheless, our study showed that women with DS have an earlier menopause and that 
age at menopause is significantly associated with age at diagnosis of dementia. 
The early menopause most likely reflects the accelerated ageing process seen in persons with Down 
syndrome, either in the brain, eye and inner ear, or sex organs and may be related to unrecognized 
genes overexpressed in the patients due to trisomy. If we use menopause as a read out of biological-
ly determined accelerated ageing, a difference of 7.4 years is expected between women with Down 
syndrome and those of the general population if all other co-morbidity is treated successfully. The 
present difference in life expectancy between women with DS and women without DS is, however, 
much larger (in the Netherlands at present about 12-15 years). The underlying mechanism in the 
association between early menopause and the risk of dementia is still unclear. As the amyloid 
deposition, which is the origin of the dementia in DS patients, already starts in the second decade 
of patients with DS, it is unlikely that menopause or the withdrawal of estrogen itself initiates 
the deposition of beta-amyloid. More likely, menopause modifies the risk of dementia. There was 
no significant difference in age at diagnosis of dementia between men and women in the total 
study population. Both male and female persons with DS show accelerated aging. This raises the 
question whether there is a similar metabolic change in men that is related to aging. Nevertheless, 
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an important clinical implication of our findings is that women with DS should be screened for 
dementia more intensively after menopause, and research on the possibility of using hormone 
replacement therapy in the elderly women with DS is warranted. 
Neopterin
Aging and dementia are accompanied by immune cell abnormalities, and in AD patients a correla-
tion between interferon-γ secretion by mononuclear cells and the AD disease state was found. Im-
munoreactions in peripheral blood in AD reflect changes occurring in the brain, and may correlate 
with the clinical stage of the disease73. Interferon γ, produced by T-lymphocytes is also capable of 
inducing the secretion of neopterin from human activated monocyte/macrophages. Recent studies 
have reported increased concentrations of serum neopterin in AD patients74-76. Persons with DS 
show an altered immune response and an increased susceptibility to AD. Neopterin levels in serum 
were found to be higher in DS persons than in controls, and the levels were not correlated with age, 
sex, APOE phenotype, and amyloid β-40 or amyloid β-4277-79. We found not only higher neopterin 
concentrations in persons with DS having many comorbidities, but also in healthy persons with 
DS compared to controls from the general population78(see chapter 3.1).
Our study is the first to show a relation between plasma concentration of neopterin and risk of 
dementia in persons with DS. The demented persons with DS had a significantly (p = 0.05) higher 
plasma neopterin concentration than the non-demented (see chapter 3.2). Compared with the DS 
without dementia, the prevalent demented persons with DS, and the incident patients who were 
non-demented at baseline but who developed dementia during the follow-up, had significantly 
higher plasma neopterin concentrations at the start of the study. After excluding those persons 
with known autoimmune disorders, the risk of developing dementia was increased by 1.83 times 
(95%CI = 1.04-3.20) in the subgroup with plasma neopterin levels above median (> 21.20nM). 
High plasma neopterin levels were shown to be an independent determinant of the risk of demen-
tia in persons with DS. 
Higher levels of neopterin have been found in patients with inflammatory diseases of the central 
nervous system, infectious disease and tumors76, 80. The higher neopterin levels seen in the DS 
persons compared with healthy controls77, 78, as well as the higher neopterin levels seen in the 
demented persons with DS compared with the nondemented persons with DS are suggestive of a 
chronic state of cellular immune activation in DS and especially in those with dementia. This find-
ing might have clinical relevance, in that it can be used to predict the risks of dementia in persons 
with DS or in that the findings can be used to initialize targeted preventive anti-inflammatory 
treatment of high risk DS persons. Although preventive trials in the general population have been 
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negative, the question whether this approach of preventive treatment works in persons with DS, 
who have an extreme high risk of dementia, still remains. 
Nitric oxide related amino acids and neopterin concentration
Chronic inflammation has been implicated not only in diseases of the periphery, but also in neuro-
degenerative disorders such as AD81. Microglia have the capacity to secrete neurotoxic substances 
that directly contribute to neurodegeneration75; therefore suppression of microglia activation 
might be considered a therapeutic goal. As discussed in the previous paragraphs, neopterin is a 
marker of cell mediated immune activation and increased levels of this substance have been found 
in AD in the general population as well as in persons with DS. Neopterin is formed as a byprod-
uct of tetrahydrobiopterin (BH4) synthesis and the latter compound is a cofactor for the enzyme 
nitric oxide synthase, which converts L-arginine into L-citrulline and NO. The ratio of the plasma 
concentrations of citrulline (Cit)-and arginine (Arg), the so-called Cit-Arg ratio, is regarded as an 
index of NO synthesis82 (see chapter 1.1, figure 2).
In our study, plasma concentrations of almost all amino acids in persons with DS differed sig-
nificantly from those of healthy controls78. The production of NO as reflected by an increased 
Cit-Arg ratio was enhanced during development of clinical dementia. The increased concentration 
of neopterin found in the group of prevalent dementia is significantly correlated with a decreased 
Cit-Arg ratio. This finding is suggestive for an increase in oxidative, inflammatory or neurode-
generative processes in dementia. An explanation for a decreased Cit-Arg ratio in this condition 
may be that there is a reduced bioavailablity of BH4, which is the cofactor for NO synthesis and 
also for the conversion of phenylalanine to tyrosine. Interestingly, the phenylalanine levels are also 
increased in the demented persons with DS as compared to those of the healthy persons. Possible 
mechanisms for the impaired bioavailability of BH4 are oxidation of the labile substance (BH4) 
due to the oxidative stress and/or depletion of BH4 due to the higher neopterin synthesis at the 
expense of BH483, 84. Since the Cit-Arg ratio is significantly higher in the incident demented cases 
and assuming that this ratio is indeed a good reflection of NO synthesis, it can be hypothesized 
that the production of NO is enhanced during the development of dementia (see chapter 3.3).
Our first findings are promising. Further studies are required to refine and validate the optimal 
neopterin cut off values in relation to the Cit-Arg ratio, together with clinical assessments, to reach 
a prognosis of dementia in persons with DS.
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Predictors of survivAl in Persons with down’s syndrome
survival in elderly persons with down’s syndrome
Our knowledge of factors influencing survival in older persons with DS is still very limited. Studies 
including persons with DS older than 60 years of age are rare. Nearly 20% of the persons with DS 
aged 45 and older suffer from dementia13, 85 and several studies have shown an increased risk of 
mortality for persons with DS and dementia or cognitive decline15, 86, 87. Cognitive decline has been 
shown to be associated with mortality in demented and non-demented elderly with and without 
DS88, 89. In addition to age, other factors that have implied an influence on mortality risk in elderly 
persons with DS are the gene encoding for apolipoprotein E (APOE)88, 90, 91 and co-morbidity3.
cognitive and functional decline
In our longitudinal study, we found, amongst the non-demented participants, that a relative pres-
ervation of cognitive and functional ability during follow-up to be associated with better survival, 
and more rapid decline to be associated with an increased risk of mortality. Although it is difficult 
to detect a decline in those with the lowest level of performance, this decline, monitored by screen-
ing tests even in this group, is related to mortality (see chapter 2.3). Mild Cognitive impairment 
(MCI) in the general population is defined as an intermediate stage between decline in cognition 
typical of brain aging and the decline characterizing dementia92. In a large number of patients, 
MCI progresses into AD93. MCI in persons with DS (MCI-DS), introduced as diagnostic identity 
by Jenkins et al94, can only be ascertained by longitudinal assessments. In our study, in all the 
non-demented persons, independently of their premorbid intellectual disability, we observed a 
decrease in cognitive and social functions during the annual assessment periods.
More extensive longitudinal studies are required in order to identify whether this decline is likely 
to be the result of normal aging in DS, of MCI-DS, or the pre-clinical onset of AD. One of the 
clinical challenges will be to discriminate between persons with a fast and those with a slower 
decline and to predict mortality. 
The impact of Apolipoprotein e on survival
In the general population, the APOEε4 allele has been related to early mortality in some studies, 
but the literature is inconsistent95, 96. The APOEε2 allele has been associated with increased longev-
ity in some but not in all studies95, 97, 98. In persons with DS, an association between the APOEε4 
allele and increased mortality in demented49, 99 and non-demented57, 90 has been reported, but a 
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meta-analysis based on data from 538 persons with DS showed no significant evidence for an 
increased mortality of APOE ε4 homozygotes with DS100. As in the general population, there is 
evidence that APOE ε2 is associated with increased longevity in some studies of DS33, 53, 101.
Several studies have reported reduced frequencies of the APOE ε4 allele in elderly persons with 
DS102, 103, suggesting that the ε4 allele may be associated with early mortality, notwithstanding the 
presence or absence of dementia. In our study cohort of elderly persons with DS, the frequency of 
APOEε4 decreased significantly after the age of 60 years (see chapter 2.2). We found an effect of 
the APOEε4 allele on mortality; the persons with one or two APOEε4 alleles have a 1.64-increased 
mortality risk (95%CI = 1.01-2.64). However, this increase did not remain significant when ad-
justing for dementia. The risk remained increased in demented persons as well as particularly in 
persons with DS without dementia. There was no detectable association between the presence 
of an APOEε2 allele and mortality (see chapter 2.3). Our results and those of others57, 90 strongly 
support the hypothesis that the presence of an ε4 allele in persons with DS is an independent risk 
factor for early mortality.
Our study focused on elderly persons with DS and we included persons of 45 years and older. 
We have no information of persons who died before the age of 45 years. The differences in allele 
distribution by age (and sex) suggest that there may be early differential morbidity. In addition to 
dementia, APOEε4 is associated with other age related diseases such as cardiovascular diseases, 
inflammation and infection. The impact of the APOE ε4 allele on early mortality, independent of 
dementia, needs to be studied.
co-morbidity and mortality
Many studies have focused on the relationship between dementia and mortality risk. However, 
only a small minority of these studies control for the confounding effects of comorbid health con-
ditions and demographic characteristics3, 6, 7, 104. In our study we found, before the age of 60 years, 
dementia to be the most important cause of death. After the age of 60, the mortality in those who 
are demented, as well as those who are not demented, at baseline, is almost the same. These results 
suggest that, somatic and physical pathology seem to become more important than dementia as 
causes of death after the age of 60, (see chapter 2.1, figure 3).
In our study cohort, we compared the cause of death in the demented and non-demented sepa-
rately. Respiratory problems have a significant higher frequency in the demented persons. Cardiac 
failure was a significant more frequently documented mortality cause in the non-demented per-
sons (Fig.1a,1b, this paragraph). However in one third of those who died, the cause of death could 
not be determined. This finding requires further clinical and pathological research.
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We found a significant increase in mortality risk for those living in institutions, the more severe 
intellectual disabled, those with epilepsy and impairments (see chapter 2.3). In contrast to the 
general population, impaired mobility, severity of intellectual disability, the presence of epilepsy 
and visual impairment, not cardiovascular risk factors or sex, predicted survival. From a popula-
tion perspective, one of the most remarkable findings was that sex did not predict mortality. It is 
most likely that the fact that mortality from cardiovascular disease is not an important cause of 
death in this population (neither in absolute numbers nor as predictors of mortality) explain this. 
Particular the finding that mobility is related to mortality opens the question whether physical 
Figure 1a The slices represent the total number of the demented persons who died during follow-up 
according to their cause of death
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Figure 1b The slices represent the total number of the non-demented persons who died during follow-up 
according to their cause of death
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training programs are of benefit to patients. Of course, we have to exclude that immobility is not 
related to morbidity. Our findings, that mobility is significantly associated to survival when adjust-
ing for comorbidity suggests this is not the case.
Clinical symptoms and signs of early disease are easily missed in persons with DS, because of 
their limited communicative skills. As a result, health problems often go undetected, increasing 
the morbidity and mortality104-106. Routine, systematic screening, using health watch programs for 
people with DS, is recommended and may minimize the morbidity and long-term complications, 
thus improving quality of life. Surprisingly little information is available on health care concerns 
of elderly persons with DS. Future research should be focused on comorbidities and mortality 
patterns that occur at later life stages. 
gender differences and survival
Whereas the general population shows a clear excess of women in the elderly, the population of 
elderly DS patients is characterized by an excess of men, which is seen consistently across popula-
tions 4, 5, 107, 108. It is hypothesized that the earlier menopause, including the reduction in estrogens 
following menopause, contributes to the earlier onset and increased risk of AD and an increased 
mortality risk in women with DS. 
In answer to the question whether there is an association between age at menopause and mortality, 
we demonstrated that there is a strong and significant correlation between age at menopause and 
age at death (Pearson ρ = 0.49; p = 0.01). Also, age at menopause was significantly associated with a 
2.05 fold increase in risk of death (95%CI = 1.33-3.16)(see chapter 2.4). In our study it is difficult to 
determine whether the relation between menopause and mortality is independent of the relation 
of menopause to dementia. Further it is unlikely that age at menopause alone, contributes to the 
excess of men in this older age group. In our study, the mean age at death in men (57.7 ± 5.4 years) 
was not significantly different (p = 0.61) from the mean age at death in women (58.3 ± 6.4years). 
Gender does not predict survival in persons with DS. Most likely this is explained by the fact that 
mortality due to cardiovascular disease is not an important cause of death in this population, in 
contrast to the general population where the risk of vascular pathology is increased in men (see 
chapter 2.3). The APOE ε4 allele was significantly (p = 0.02) less frequent in women than in men 
(20.9 versus 31.1%). One could hypothesize that before study entry, APOE ε4 related diseases are 
more frequent in women, and increase mortality risk early in life. One may speculate that the early 
morbidity related to APOE may be related to risk and mortality of inflammation and infectious 
disorders which typically have a higher frequency in women. Further research will be necessary 
to understand the complex relationship between sex and life expectancy in this elderly population 
with DS.
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suggestions for future reseArch
Because of the major advances in care and medical treatment, there has been a steady improve-
ment in the life expectancy and the quality of life for persons with Down’s syndrome. However, 
increased life expectancy has given rise to additional medical and social concerns related to aging 
of persons with DS. A large number of persons with DS will develop Alzheimer’s disease (AD) 
neuropathology in the brain, and comorbidity associated with accelerated aging. It is very im-
portant to understand the factors that contribute to this development. However, not all patients 
develop dementia and the challenge will be to unravel those factors that protect these patients.
As mentioned earlier, our study is one of the largest population-based studies to date. We found 
that despite the exponential increase in prevalence with age, the prevalence of dementia in the 
eldest persons with DS was not higher than 25.6%, which is substantially lower than expected 
based on literature (chapter 2.1). This finding opens the opportunities for research on, perhaps 
preventable causes of AD and mortality. Longitudinal measurements, in large population based 
multicentre cohorts is useful for predicting the early signs of dementia, and the comorbidity in-
creasing the risk of developing dementia. One of the first clinical targets will be to explore the role 
of (treatment of) comorbidity and to determine the cause(s) of mortality. However, also other 
avenues exploiting the opportunities in genomics and proteomics should be explored.
There is consensus that the presence of the APOEε4 allele is associated with increased risk of 
dementia (chapter 2.2). Besides Amyloid Precursor Protein (APP) gene, other genes that are over-
expressed by the triplication of chromosome 21, have received less attention in epidemiological 
studies. Nor has there been interest in genes regulated by chromosome 21 genes. Sequencing of 
human chromosome 21 and subsequently of its orthologues on mouse chromosome 16 has cre-
ated an opportunity for exploring the relationship between various DS phenotypes and the extra 
copy of the genes on chromosome 21109. Another very important step will be the identification of 
the function of the proteins encoded by all the genes on chromosome 21. But also genome wide 
association studies and studies comparing RNA expression and proteomics profiles of persons that 
do and do not develop dementia will ultimately bring to light which are the key genes and proteins. 
As data from functional genomics and proteomics projects grow, correlations among datasets will 
emerge and may be expected to lead to helpful insights.
Relative preservation of cognitive and functional ability is associated with better survival in this 
study population and more rapid decline is associated with an increased risk of mortality. (chap-
ter 2.3). Differential diagnostic procedures are needed to discriminate between Mild Cognitive 
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Impairment in DS (MCI-DS), and preclinical stages of dementia. The use of neuroimaging tech-
niques may make it possible to link the neuropathology and clinical signs to determine which 
forms of pathology are significant for dementia and to establish diagnostic criteria.
There has been major improvement in the life expectancy of patients with DS. However, the deter-
minants of morbidity and mortality late in life remain far from being understood. Age, dementia 
and mobility restrictions are the major predictors of survival in elderly persons with DS (chap-
ter2.3). There is a need to study whether physical exercise programs, to promote mobility in the 
elderly persons with DS, not only may improve their mobility but also their quality of life.
Perhaps the most important and difficult questions from a clinical and ethical perspective, is 
whether the present available amyloid beta (β) treatment (A β-42 immunization) should be tested 
in a clinical trial in persons with DS. Although findings in the general population have been disap-
pointing in that the amyloid β removal from the brain in patients with AD does not improve the 
cognitive function or survival110. It is widely acknowledged that a problem in the interpretation of 
the findings is that the treatment is likely to be effective only early in the disease process. In persons 
with DS, in whom the amyloid deposition starts already in the second decade, early preventive 
treatment, using amyloid β withdrawal is of interest. The high risk of patients, in particular in 
APOE ε4 carriers and the cause of dementia (overexpression of APP) make it likely that powerful 
trials can be conducted. However, so far ethical discussions have prevented these trials in the USA, 
this discussion should be opened in the Netherlands. Although there are obvious ethical argu-
ments against using amyloid β treatment in persons with DS, due to known complications. One 
may also argue that it is not ethical to withhold treatment to this group who, on scientific grounds, 
may benefit from early treatment.
This thesis, rather serves as a starting point of new research, than as an endpoint. Understanding 
the factors that contribute to the longevity in DS will be the major challenge for clinical investiga-
tors in the coming decade. 
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summAry
Accelerated ageing and increased risk of Alzheimer’s disease (AD) are characteristics of persons 
with Down’s syndrome (DS). Due to improvements in medical treatment, life expectancy has in-
creased enormously. In the Netherlands, estimates of life expectancy show that 44% of persons 
with DS will reach the age of 60. However, this has not changed the fact that there is still a lower 
life expectancy by 15 to 20 years compared with the general population. At present, AD appears to 
be the most important cause of morbidity and mortality among elderly persons with DS and is the 
focus of the studies in this thesis. 
In chapter 2.1 one of the largest population-based studies in elderly persons with DS to date is 
presented. The study was performed in the south and southwest of the Netherlands. In total, 506 
persons with DS, aged 45 and above, were recruited between 1 December 1999 and 1 December 
2003. All participants were monitored annually, up to the reference date of January 1, 2007. At 
the time of study entry, each person received a complete assessment including interviews with 
relatives, carers and the general practitioner. All persons obtained a general physical and neuro-
logical examination and, if compliant, a venapuncture. The diagnosis of dementia was based on 
the ICD-10 Symptom Checklist for Mental Disorders and according to the guidelines produced by 
the Ageing Special Interest Group of the International Association for the Scientific Study of Intel-
lectual Disabilities (IASSID). The overall prevalence of dementia was 16.8% (85 cases). There was 
no significant difference in gender and in the pre-morbid cognitive level between the persons with 
dementia and those without dementia. Persons with dementia were more often institutionalized. 
The demented persons also were more frequently treated with anti-epileptic and anti-psychotic 
drugs. Sensory problems were not associated with dementia in this study population.
The prevalence of dementia increased from 8.9% in the 45 to 49-age category to 32.1% in the 55 to 
59-age category, but did not increase above the age of 60, the prevalence of dementia in the eldest 
persons with DS was not higher than 25.6. 
The apolipoprotein E gene (APOE), especially the APOEε4 allele, is consistently associated with 
dementia in the general population. In chapter 2.2, the effect of APOE on dementia in this study 
was described. There was significant evidence of an APOE ε4 effect on the rate of decline in social 
and daily living skills. In particular DS persons who were homozygous for APOEε4 showed a 
larger decrease in function using the SRZ, independent of their pre-morbid level of functioning. 
We found a modest but not statistical significant effect on the prevalence of dementia. We did 
observe a significant long-term effect on the incidence of dementia, in the presence of an APOEε4 
allele the risk to develop dementia during follow-up was 4,66 times increased. When pooling these 
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data in a meta-analysis, the APOEε4 allele shows a significant 1.59-fold increase in risk of demen-
tia, indicating that that APOE is influencing the risk of dementia in persons with DS.
Our knowledge of factors that influence survival in older persons with DS is still very limited. In 
chapter 2.3, the study of the impact of cognitive and functional decline and physical comorbidity 
on mortality risk over time is presented. After a mean follow-up time of 4.5 years (range 0.0-7.6 
years), there was no significant difference in the mean age at death between men and women (57.7 
versus 58.4 years). Older persons at baseline, those with physical handicaps, those living in the 
institutions, and those with a severe to profound level of intellectual disability were more likely to 
die during follow-up. Relative preservation of cognitive and functional ability, as measured using 
two screening instruments, DMR and SRZ, is associated with better survival in this study popula-
tion. We found an effect of the APOEε4 allele on mortality. The persons with one or two APOEε4 
alleles have a 1.64-increased mortality risk. However, this increase did not remain significant when 
adjusting for dementia. Finally, using all known risk factors in a multivariate survival analysis, 
only dementia, age at baseline and a restricted mobility, remained significantly associated with 
mortality risk. 
In chapter 2.4, as an indication of the precocious aging in women with DS, age at menopause is 
described and related to survival and also to age at diagnosis of dementia. We determined the exact 
age of natural menopause in 85 (55%) of the postmenopausal women. The mean age of menopause 
is relatively early (44 years) compared to that seen in the general population (51.4 years). Age at 
menopause is significantly correlated with age at diagnosis of dementia, and is significantly as-
sociated with a 1.82-increased risk of dementia. There also is a strong and significant correlation 
between age at menopause and age at death. Age at menopause was significantly associated with a 
2.05-increased risk of death.
Chapter 3 focuses on biochemical pathways involved in the development of dementia in persons 
with DS. In chapter 3.1, a study is described which focussed on peripheral biochemical param-
eters that reflect changes in homocysteine metabolism, immune function and monoaminergic 
neurotransmission. The study group comprised 48 healthy persons with DS and was compared 
with 48 age and sex matched healthy controls from the general population. It was found that nearly 
all values of amino acids are lower in the persons with DS as compared to controls. With respect to 
neopterin, values in the DS group are significantly increased as compared to the control group. Fur-
thermore, plasma homovanillic acid (HVA) levels are significantly higher in the DS group, whereas 
no differences are found regarding 5-hydroxyindoleacetic acid (5-HIAA) concentrations. 
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In chapter 3.2, the relation between plasma concentration of neopterin and (risk of) dementia 
in persons with DS is presented. Compared with the DS persons without dementia, the prevalent 
demented persons with DS, and those persons who were non-demented at baseline but who de-
veloped dementia during the follow-up, had significantly higher plasma neopterin concentrations 
at the start of the study. When excluding from the analyses those persons with known autoim-
mune disorders, the risk of developing dementia was almost doubled in the subgroup with plasma 
neopterin levels above median (> 21.20nM). Our findings suggest that elevated plasma concentra-
tion of neopterin in non-demented persons with DS is an independent determinant of the risk 
dementia. 
In chapter 3.3 we focus on the spectrum of amino acids, the concentration of neopterin, and the 
role of nitric oxide (NO). Special attention was given to those amino acids, involved in the oxida-
tive processes and their relation to the development of Alzheimer’s disease.
The production of NO, as reflected by an increased citrulline/arginine (Cit-Arg) ratio, was en-
hanced during development of clinical dementia. In the group of prevalent dementia the enhanced 
concentration of neopterin is significantly correlated with a decreased Cit-Arg ratio. This finding 
implies an increase in oxidative, inflammatory or neurodegenerative processes in dementia in 
persons with DS.
Finally, in chapter 4, all findings are put into perspective and future prospects and challenges are 
discussed. 
Chapter 5
154
sAmenvAtting
Kenmerkend voor het Down syndroom is het optreden van een vroegtijdige veroudering, en daar-
mee samenhangend een verhoogd risico op het krijgen van de ziekte van Alzheimer. De levens-
verwachting van mensen met dit syndroom is de laatste jaren enorm toegenomen, vooral door 
de verbetering van de medische zorg. In Nederland wordt 44% procent van de mensen inmiddels 
ouder dan 60 jaar. Desondanks is de gemiddelde levensverwachting 15 tot 20 jaar korter dan die 
van de mensen in de totale bevolking. In dit onderzoek hebben we ons met name geconcentreerd 
op de ziekte van Alzheimer omdat dit de belangrijkste oorzaak is van ziekte en sterfte bij ouderen 
met het Down syndroom. 
In hoofdstuk 2.1 wordt de uitvoering van het onderzoek beschreven.
Alle organisaties, in het zuiden en zuidoosten van Nederland, betrokken bij de zorg voor ver-
standelijk gehandicapten, werden uitgenodigd om deel te nemen aan dit longitudinale onderzoek. 
Tussen december 1999 en december 2003 werden in totaal 506 mensen met het Down syndroom 
bereid gevonden mee te doen in deze studie. Bij de start van het onderzoek kregen alle deelnemers 
een oriënterend lichamelijk, intern en neurologisch onderzoek en indien mogelijk een bloedon-
derzoek. Er werden van alle deelnemers uitgebreide gegevens verzameld. Tussen 1999 en 2007 
werd jaarlijks contact opgenomen met de begeleiding om, middels vragenlijsten, het functioneren 
te kunnen volgen.
De diagnose dementie werd vastgesteld aan de hand van de ICD-10 criteria en de richtlijnen zoals 
die zijn opgesteld door de “the Ageing Special Interest Group of the International Association for 
the Scientific Study of Intellectual Disabilities (IASSID)”. Volgens deze criteria is het belangrijk een 
achteruitgang in functioneren in de loop der tijd vast te stellen, ongeacht het niveau van functio-
neren. Deze achteruitgang moet groter zijn dan die welke op grond van leeftijd, en van normale 
veroudering, te verwachten is.
Bij de aanvang van het onderzoek werd bij 85 deelnemers dementie vastgesteld, dit betekent een 
prevalentie van 16.8%. Het prevalentie percentage was niet afhankelijk van geslacht en het niveau 
van functioneren. We stelden vast dat dementerende mensen vaker in een instituut wonen en 
opmerkelijk meer anti-epileptische- en antipsychotische medicatie krijgen. Er is geen relatie vast-
gesteld tussen het voorkomen van dementie en de aanwezigheid van zintuig stoornissen.
De prevalentie van dementie, nam toe per leeftijdscategorie; van 8.9% in de categorie 45 tot 49 
jarigen, tot 32.1% in de leeftijds categorie 55 tot 59 jarigen. Ondanks deze exponentiele toename 
in prevalentie per leeftijdscategorie, stelden we een daling in de prevalentie in de leeftijdscategorie 
boven de 60 jaar vast. In tegenstelling tot wat men zou verwachten was de prevalentie in deze 
oudste categorie niet hoger dan 25.6%.
summary
155
In de gewone bevolking wordt het Apolipoproteine E (APOE) gen en vooral het APOEε4 allel ge-
associeerd met een vier tot acht keer verhoogd risico op het optreden van dementie. In hoofdstuk 
2.2 wordt de studie naar de invloed van het APOE gen op het optreden van dementie bij mensen 
met het Down syndroom beschreven.
We stelden een duidelijk effect van de aanwezigheid van een APOEε4 allel vast op de mate van ach-
teruitgang tijdens de onderzoek periode. Deelnemers, homozygoot voor het APOEε4 allel, lieten 
een significant grotere daling in functioneren zien, zoals vastgelegd met behulp van SRZ scores, 
onafhankelijk van hun intelligentie niveau. In onze onderzoekspopulatie stelden we een effect vast, 
zij het niet significant, van de aanwezigheid van het APOEε4 allel op de prevalentie van dementie. 
Na tenminste drie jaar follow-up, blijkt de aanwezigheid van tenminste een APOEε4 allel, een 
significant, 4.66 keer verhoogd risico te betekenen voor het ontwikkelen van dementie tijdens 
de onderzoek periode. Tevens wordt er een significant, 1.59 keer verhoogd risico op dementie 
gevonden, na het samenvoegen van onze data met die van anderen in een meta-analyse. We mogen 
concluderen dat het APOE gen, ook bij mensen met het Down syndroom, een invloed heeft op het 
ontwikkelen van dementie.
Alhoewel de levensverwachting van mensen met het Down syndroom enorm is toegenomen, 
weten we weinig van de factoren die deze levensverwachting beïnvloeden. In hoofdstuk 2.3 wor-
den de resultaten gepresenteerd van het onderzoek naar de invloed van cognitieve en functionele 
achteruitgang, alsook de invloed van co-morbiditeit op het percentage van de mensen die sterven 
tijdens de onderzoek periode. Na een gemiddelde onderzoekstijd van 4.5 jaar (minimum 0.0- 
maximum 7.5 jaar), werd er geen verschil in leeftijd vastgesteld waarop mannen (± 57.7 jaar) en 
vrouwen (± 58.4 jaar) overlijden. Mensen waarbij de cognitieve en functionele vaardigheden rela-
tief intact bleven, habben een grotere kans om te overleven. Tevens stelden we vast dat het APOEε4 
allel invloed heeft op het risico om te overlijden, de aanwezigheid van een APOEε4 allel, betekent 
een 1.64 verhoogd sterfterisico. Leeftijd, ernst van de verstandelijke handicap, de leefsituatie (ge-
institutionaliseerd in tegenstelling tot wonen in de maatschappij), de dementie status, epilepsie, 
mobiliteit, visusstoornissen en de aanwezigheid van een APOEε4 allel zijn significant geassocieerd 
met het risico om te overlijden. Wanneer we in één model (multivariate survival) deze significante 
factoren tegelijkertijd bestuderen, zien we dat er slechts drie factoren overblijven, namelijk leeftijd, 
dementie, en een beperking in de mobiliteit, die van invloed zijn op een groter sterfte risico.
Een vroege menopauze zou men kunnen zien als een symptoom van een versnelde veroudering. In 
hoofdstuk 2.4 beschrijven we de resultaten van een onderzoek naar de relatie tussen de leeftijd van 
menopauze en de leeftijd waarop dementie is gediagnosticeerd en de leeftijd waarop de vrouwen 
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met het Down syndroom in deze studie overlijden. Vrouwen met het Down syndroom komen eer-
der in de menopauze (gemiddeld op een leeftijd van 44 jaar) dan vrouwen in de gewone bevolking 
(gemiddeld 51.4 jaar). De leeftijd waarop de menopauze begint blijkt significant gecorreleerd te 
zijn met de leeftijd waarop de dementie werd vastgesteld en een vroege menopauze (jonger dan 45 
jaar) is geassocieerd met een 1.82 verhoogd risico op het krijgen van dementie. De leeftijd waarop 
de vrouwen sterven is eveneens significant geassocieerd met de leeftijd waarop de menopauze 
begint en een vroege menopauze betekent een 2.05 verhoogd risico om te overlijden tijdens de 
onderzoeksperiode. Deze vroege menopauze zou veroorzaakt kunnen worden door een versnelde 
veroudering, ofwel in de hersenen, in de geslachtsorganen, dan wel door overexpressie van genen 
ten gevolge van de trisomie van chromosoom 21. Het is duidelijk dat een vroege menopauze sa-
menhangt met een eerder optreden van dementie, een hoger risico op het krijgen van dementie en 
mogelijk hieraan gerelateerd een hoger sterfte risico.
hoofdstuk 3 beschrijft een aantal biochemische processen die mogelijk een rol kunnen spelen bij 
het ontwikkelen van dementie bij mensen met het Down syndroom.
In hoofdstuk 3.1 richten we ons op perifere biochemische parameters die betrokken zijn bij het 
homocysteine metabolisme, de immuun functie, en de monoaminerge neurotransmissie. Een 
groep van 48 gezonde mensen met het Down syndroom, werd vergeleken met een op leeftijd en 
geslacht gematchte controle groep, uit de algemene bevolking. Het spectrum van aminozuren in 
de Down syndroom groep laat significante afwijkingen zien in vergelijking met de controle groep. 
Het meest opvallend zijn de verhoging van de taurine en de verlaging van de methionine, wat kan 
wijzen op neurodegeneratieve processen. De concentratie van neopterine, een pteridine, die geas-
socieerd wordt met de cellulaire immunrespons, blijkt hoger te zijn in de groep van mensen met 
het syndroom van Down in vergelijking met de controle groep. Homovanilline zuur is verhoogd, 
wat zou kunnen samenhangen met een toegenomen dopamine turnover.
In hoofdstuk 3.2 beschrijven we de relatie tussen de plasma concentratie van neopterine en het 
ontwikkelen van dementie tijdens de onderzoek periode. De prevalent demente deelnemers en 
degene die dementie ontwikkelden tijdens de onderzoek periode hebben een hogere plasma neo-
pterine concentratie dan de niet demente deelnemers. Wanneer we de deelnemers met een auto-
immuun aandoening buiten beschouwing laten, blijkt het risico op het ontwikkelen van dementie 
in de groep met een boven gemiddelde neopterine concentratie (>21.20nM) bijna te verdubbelen. 
Een hoge plasma concentratie van neopterine lijkt een marker te zijn voor een verhoogd risico op 
dementie.
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In hoofdstuk 3.3 richten we onze aandacht opnieuw op het spectrum van aminozuren, de 
concentratie van neopterine en tevens op de rol van nitriet oxide in relatie tot de ontwikkeling 
van dementie. We bestudeerden met name de aminozuren die betrokken zijn bij de oxidatieve 
processen in relatie tot de ontwikkeling van de ziekte van Alzheimer. De productie van nitriet 
oxide, weergegeven door de citrulline/arginine ratio, is toegenomen in de groep van de mensen 
die dementie ontwikkelden tijdens de onderzoek periode. In de groep van de prevalent dementen 
blijkt de verhoogde neopterine concentratie significant gecorreleerd aan een verlaagde citrulline/
arginine ratio. Uit deze bevindingen mogen we concluderen dat er sprake is van toegenomen oxi-
datieve, inflammatoire en neurodegeneratieve processen gedurende het ontwikkelen van dementie 
bij mensen met het Down syndroom.
In hoofdstuk 4 tenslotte, zijn alle bevindingen besproken en in perspectief geplaatst. Vooruit-
zichten voor klinisch onderzoek, onderzoek naar de co-morbiditeit en de mogelijke behandeling, 
worden beschreven.
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